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5ABSTRACT
Steroid hormones (sex steroids, glucocorticoids and mineralocorticoids) control a wide
range of biological functions connected to growth, development and homeostasis. The
effects of steroid hormones are mediated by specific steroid receptors that are sequence-
specific transcription factors belonging to the large family of nuclear receptors. The steroid
receptors are activated upon ligand binding, which leads to dimerization of the receptors
and binding to the promoter regions of their target genes. An increasing number of nuclear
receptor coregulator proteins have been identified that interact with the receptors and either
enhance or repress nuclear receptor-dependent transcription. ARIP3/PIASxα is an
androgen receptor (AR)-interacting protein that modulates transcriptional activity of the
receptor. It belongs to the PIAS (protein inhibitor of activated STAT) protein family,
which also includes Miz1/PIASxβ, GBP/PIAS1, PIAS3 and PIASγ/y. Other PIAS family
members have been shown to interact with and to modulate the activities of very dissimilar
proteins. However, the high degree of sequence homology among PIAS proteins predicts
similar functions. In this study, it was demonstrated that, in addition to ARIP3, also other
PIAS proteins are able to modulate steroid receptor-dependent transcription albeit to a
differential degree, depending on the receptor, the promoter and the cell type.
The activities of proteins are regulated by various covalent modifications, such as
glycosylation, phosphorylation, acetylation, methylation and ubiquitination. Covalent
modifications of histones and non-histone proteins involved in the regulation of
transcription modulate the functions of these proteins and thus have an influence on the
transcriptional output. SUMO-1 (small ubiquitin-related modifier) modification leads to
attachment of SUMO-1 to specific lysine residues of target proteins in a reaction
mechanistically related to ubiquitination pathway. The biological importance of SUMO-1
modification is still unclear, but there is compelling evidence for an important role of
sumoylation in the regulation of protein targeting and protein-protein interactions.
Activities of transcription factors are also modulated by covalent SUMO-1 modifications.
In this study, ARIP3 and other PIAS proteins were shown to interact with SUMO-1
and its E2-type conjugase Ubc9. PIAS proteins were also targets for SUMO-1
modification, and they bound other sumoylated proteins in a non-covalent fashion.
Importantly, a novel function for the PIAS proteins was discovered, and ARIP3 and PIAS1
were demonstrated to act as E3 SUMO-1 ligases capable of enhancing sumoylation of
several transcriptional regulators such as AR, c-Jun and the coactivator protein GRIP1. The
SUMO ligase activity of PIAS proteins was dependent on the PIAS RING finger-like
domain that was also critical for PIAS proteins to function as steroid receptor coregulators.
The most of the effects of PIAS proteins on steroid receptor-mediated signaling were
suggested to be exerted through SUMO E3 ligase and SUMO-tethering activities.
Consistent with the ability of PIAS proteins to enhance sumoylation of GRIP1, PIAS
proteins and GRIP1 interacted with each other and cooperated in steroid receptor-
dependent transcription. In keeping with these results, mutation of the main SUMO-1
attachment sites of GRIP1 blunted its coactivator function and abolished the cooperation
with PIAS proteins. In summary, this study has clarified the function of PIAS proteins and
the mechanisms of steroid hormone signaling. Furthermore, these results suggest an
emerging importance of SUMO-1 modifications in the regulation of transcription.
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7ABBREVIATIONS
AD activation domain
AF activation function
AIS androgen insensitivity syndrome
AR androgen receptor
ARE androgen response element
ARIP3 androgen receptor-interacting protein 3
CARM1 coactivator-associated arginine methyltransferase 1
CBP CREB-binding protein
COS-1 SV40 transformed monkey kidney cell line
CREB cAMP responsive element-binding protein
CTD C-terminal domain of the largest subunit of RNA polymerase II
DBD DNA-binding domain
DRIP vitamin D receptor-interacting protein
EGFP enhanced green fluorescent protein
ER estrogen receptor
ERE estrogen response element
GBP Gu/RNA helicase II-binding protein
GR glucocorticoid receptor
GRIP1 glucocorticoid receptor-interacting protein 1
GST glutathione S-transferase
GTF general transcription factor
HAT histone acetyltransferase
HDAC histone deacetylase
HeLa human cervix carcinoma cell line
HMG high mobility group
Hsp heat shock protein
LBD ligand-binding domain
LUC luciferase
Miz1 Msx-interacting zinc finger
MMTV mouse mammary tumor virus
MR mineralocorticoid receptor
N-CoR nuclear receptor corepressor
NID nuclear receptor interaction domain
NR nuclear receptor
NTD N-terminal domain
PIAS protein inhibitor of activated STAT
PIC preinitiation complex
PML promyelocytic leukemia gene product
PPAR peroxisome proliferator-activated receptor
PR progesterone receptor
RAR retinoid acid receptor
RNAP II RNA polymerase II
RXR retinoid X receptor
SAP SAF-A/B, Acinus and PIAS motif
SMRT silencing mediator for retinoic acid and thyroid hormone receptors
SRC steroid receptor coactivator
STAT signal transducers and activators of transcription
SUMO-1 small ubiquitin-like modifier 1
TAF TBP-associated factor
TBP TATA-binding protein
TR thyroid hormone receptor
TRAP thyroid hormone receptor-associated protein
UBA ubiquitin-associated domain
Ubc9 ubiquitin-conjugating enzyme 9 (SUMO-conjugating E2 enzyme)
UIM ubiquitin-interacting motif
VDR vitamin D3 receptor
ZF zinc finger
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1. PIAS PROTEIN FAMILY
The PIAS protein family is a small group of nuclear proteins, including PIAS1/GBP,
PIAS3, ARIP3/PIASxα, Miz1/PIASxβ and PIASγ/y (Chung et al. 1997, Valdez et al.
1997, Wu et al. 1997, Liu et al. 1998, Moilanen et al. 1999, Sturm et al. 2000). The
members of the PIAS family were found in yeast two-hybrid screens using various
proteins, mostly transcription factors, as baits. In addition to these interactions, PIAS
proteins have recently been reported to interact with and to modulate the activities of
number of other proteins. PIAS proteins are evolutionary conserved, since homologues of
mammalian PIAS proteins are found in many nonvertebrate animal species and even in
plants. For example, a protein encoded by the Drosophila melanogaster gene Zimp (Mohr
and Boswell 1999), a predicted Caenorhabditis elegans protein, the Saccharomyces
cerevisiae septin-interacting protein Nfi1p and putative proteins from
Schizosaccharomyces pombe, Vicia faba and Arabidopsis thaliana share sequence
homology with PIAS proteins. The physiological importance of PIAS proteins is
underscored by the finding that Zimp is an essential gene in Drosophila (Mohr and
Boswell 1999).
1.1. Discovery of PIAS proteins
The PIAS protein family is named according to the members that were first characterized
in cytokine signaling as Protein Inhibitors of Activated STATs (signal transducer and
activator of transcription). PIAS3 (protein inhibitor of activated Stat3) was demonstrated to
interact with Stat3 and inhibit Stat3-dependent signaling (Chung et al. 1997). PIAS1 was
found in a yeast two-hybrid screen of a human B cell library with Stat1 devoid of the C-
terminal transcriptional activation domain as bait (Liu et al. 1998). The other PIAS family
members PIAS3, PIASxα, PIASxβ and PIASy were found by EST database searching and
library screening using the PIAS1 sequence as a probe (Liu et al. 1998). PIAS proteins
have also been found to interact with other proteins unrelated to the STATs. Miz1 (Msx-
interacting zinc-finger) was found in a yeast two-hybrid screen using a mouse E14.5 day
cDNA library and full-length Msx2 as bait (Wu et al. 1997). Msx2 is a homeodomain-
containing protein that functions in the regulation of inductive tissue interactions (Wu et al.
1997). Wu et al. described Miz1 as a sequence-specific DNA-binding protein and a
positive-acting transcription factor that is able to enhance the DNA binding of Msx2. Miz1
is a mouse counterpart of human PIASxβ, but the Miz1 form studied by Wu et al. lacked
the nucleotides encoding the first 131 amino acids of PIASxβ. ARIP3 ( androgen receptor-
interacting protein 3) was discovered when a region of androgen receptor (AR) including
9the DNA-binding domain and part of the hinge region was used as bait to screen a mouse
embryo E10.5 library (Moilanen et al. 1999, Fig. 1). Rat ARIP3 corresponds to human
PIASxα. The first 550 amino acids of PIASxα and PIASxβ are identical, and they differ
only in their C termini. Thus, they most probably represent splicing variants encoded by
the same gene. Gu/RNA helicase II-binding protein (GBP) bound to the helicase II in a
yeast two-hybrid screen using a human B lymphocyte cDNA library (Valdez et al. 1997).
GBP is almost identical to PIAS1; it lacks only the first nine amino acids, and displays a
few amino acid differences when compared to PIAS1 sequence. KChAP (K+ channel-
associated protein) was discovered when a yeast two-hybrid screen of rat brain cDNA
library was performed with the full-length Kvβ1.2 subunit of the K+ channel as bait (Wible
et al. 1998). Rat KChAP is almost identical to PIAS3, and it was termed PIAS3β to
distinguish it from the original mouse PIAS3 clone (Wible et al. 2002). The N-terminal
region of KChAP contains an in-frame insertion of 39 amino acids, which is lacking from
mouse PIAS3 but not from human PIAS3.
Fig. 1. Schematic structure of ARIP3. Arrows depict LXXLL motifs starting form amino acids 19 and 304,
and related LXXLI motifs starting from amino acids 157 and 399. The SAP motif, the putative RING finger-
like structure, the SUMO-1 binding motif, and the region found to interact with AR in a yeast two-hybrid
screen are indicated.
1.2. Structure of PIAS proteins
PIAS proteins share a high degree of sequence homology with the most conserved regions
being the first 60 amino acids at their N terminus and the central domain containing a
putative zinc-binding structure. The serine-rich C terminus of PIAS proteins is the least
conserved part. In the N terminus, PIAS proteins have a SAP (SAF-A/B, Acinus and
PIAS) motif predicted to be involved in sequence- or structure-specific DNA binding (Fig.
1, Aravind and Koonin 2000). SAP motif is found in the sequences of many chromatin-
associated proteins, such as the scaffold attachment factors A and B (SAF-A and -B), plant
poly(ADP-ribose) polymerase (PARP) and human Acinus (Romig et al. 1992, Renz and
Fackelmayer 1996, Sahara et al. 1999). SAF-A and -B are nuclear proteins that bind to AT-
rich chromosomal regions known as scaffold- or matrix-attachment regions (SAR/MAR)
(Romig et al. 1992, Renz and Fackelmayer 1996). Mutations of SAF-A SAP motif result in
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a complete loss of the DNA-binding activity (Göhring et al. 1997). By targeting proteins to
specific chromosomal locations, SAP motif may contribute to the coupling of transcription
with splicing and repair and to apoptotic degradation of chromatin (Aravind and Koonin
2000).
Fig. 2. Sequence alignment of the potential zinc finger region of PIASx and related proteins. The region of
human (h) PIASxα containing the zinc finger structure (protein database sequence identification number
GI:3643113; amino acids 332–428) was aligned with the same region of related proteins. hPIAS3 (4996563,
amino acids 304–400); hPIAS1 (3643107, amino acids 320–416); hPIASy (7706230, amino acids 312–408);
zimp = Drosophila Zimp-A (4761232, amino acids 311–410); ce = a predicted C. elegans protein (7509196,
amino acids 357–453); Nfi1p = S. cerevisiae Nfi1 protein (2498628, amino acids 324–421); sp = a predicted
protein from S. pombe (7493364, amino acids 291–388); vf = V. faba protein (2104683, amino acids
303–400). Black boxes and gray shadings depict amino acids that are identical or conserved among the
sequences, respectively. Conserved cysteines (at least in four family members) and histidine are indicated by
arrows, and the circle depicts the conserved Trp residue.
The central part of PIAS proteins is predicted to form a zinc-binding structure,
termed Miz Zn-finger (Wu et al. 1997). All PIAS proteins except PIAS3, harbor seven
cysteine residues and a histidine residue which are mandatory for a C3HC4-type RING
finger motif (Fig. 2, Joazeiro and Weissman 2000). Threading analysis of this PIAS region
suggests that its three-dimensional structure is similar to a C3HC4 RING finger fold.
However, the spacing between potential zinc-coordinating residues and the amino acid
composition of mammalian PIAS RING-like structure differ substantially from the C3HC4
RING finger. Interestingly, PIAS3 does not have a cysteine residue at the fourth position of
the putative C3HC4 motif.
The LXXLL motif is a short amino acid sequence involved in interactions of
coactivators with the ligand-binding domain (LBD) of nuclear receptors (Heery et al.
1997). PIAS proteins have two LXXLL motifs starting at residues 19 and 304 in the
ARIP3 sequence. The N-terminal LXXLL motif of PIASy is not involved in binding to
hPIASx    332 DSEIATTSLRVSLMCPLGKMRLTIPCRAVTCTHLQCFDAALYLQMNEKKPTWICPVCDKK
hPIAS3    304 DSEVATTSLRVSLMCPLGKMRLTVPCRALTCAHLQSFDAALYLQMNEKKPTWTCPVCDKK
hPIAS1    320 DSEIATTSLRVSLLCPLGKMRLTIPCRALTCSHLQCFDATLYIQMNEKKPTWVCPVCDKK
hPIASy    312 DSEIATTGVRVSLICPLVKMRLSVPCRAETCAHLQCFDAVFYLQMNEKKPTWMCPVCDKP
zimp      311 DCEIATTMLKVSLNCPLGKMKMLLPCRASTCSHLQCFDASLYLQMNERKPTWNCPVCDKP
ce        357 -DDIAMDRLNISLLDPLCKTRMTTPSRCQDCTHLQCFDLLSYLMMNEKKPTWQCPVCSSN
Nfi1p     324 DDDIITTSTVLSLQCPISCTRMKYPAKTDQCKHIQCFDALWFLHSQSQVPTWQCPICQHP
sp        291 DADIIATSTDISLKCPLSFSRISLPVRSVFCKHIQCFDASAFLEMNKQTPSWMCPVCASH
vf        303 DSDIIEGASRFSLNCPISFTRIKTPVKGRSCKHFQCFDFDNFIKINSKRPSWRCPHCNQN
hPIASx   AAYESLILDGLFMEILN---DCSDVDEIKFQEDGSWCPMR 428
hPIAS3   APYESLIIDGLFMEILS---SCSDCDEIQFMEDGSWCPMK 400
hPIAS1   APYEHLIIDGLFMEILK---YCTDCDEIQFKEDGTWAPMR 416
hPIASy   APYDQLIIDGLLSKILS---ECEDADEIEYLVDGSWCPIR 408
zimp     AIYDNLVIDGYFQEVLGSSLLKSDDTEIQLHQDGSWSTPG 410
ce       CPYDRLIVDDYFLDMLAK--VDKNTTEVELKEDGSYDVIK 453
Nfi1p    IKFDQLKISEFVDNIIQN--CNEDVEQVEISVDGSWKPIH 421
sp       IQFSDLIIDGFMQHILES--TPSNSETITVDPEGNWKLNT 388
vf       VSYTEIRLDRNMIEILEK--VGENIVEVTVHADGSWQPVL 400
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Stat1 or AR, but it is required for its inhibitory activity (Gross et al. 2001, Liu et al. 2001).
PIAS proteins harbor a motif containing Ser and Glu/Asp residue-rich stretches preceded
by hydrophobic residues C-terminal to the zinc-binding structure of PIAS proteins (amino
acids 472-482 in ARIP3 sequence). A similar motif from the PM-Scl75 protein is
suggested to act as a SUMO-1-interacting motif since it is sufficient for the interaction of
PM-Scl75 with SUMO-1 in yeast (Minty et al. 2000).
1.3. Expression of PIAS proteins
The genes encoding PIAS proteins are located in distinct chromosomes in the human
genome. The PIASy gene has been mapped to chromosomal location 19p13.3 (Sturm et al.
2001), the PIAS3 gene was localized to chromosome 1 (1q21) (Ueki et al. 1999) and the
PIAS1 gene to chromosome sub-band 15q22 (Weiskirchen et al. 2001). BLAST search
localized the PIASx gene to chromosome 18. ARIP3/PIASxα, PIAS1/GBP and PIASy are
mainly expressed in testis, but low levels of mRNAs are also detected in other tissues
(Valdez et al. 1997, Moilanen et al. 1999, Tan et al. 2000, Gross et al. 2001). In addition,
EST database search with PIAS sequences revealed distribution of PIAS proteins in
various tissues. Immunostaining of adult rat testis localized ARIP3 protein in the nuclei of
Sertoli cells, spermatogonia, and primary spermatocytes (Moilanen et al. 1999). Likewise,
PIAS1 protein is expressed in Sertoli cells, Leydig cells and spermatogenic cells including
spermatocytes and round spermatids (Tan et al. 2000). Expression of PIAS1, PIASxα and
PIASxβ mRNA is detected by in situ hybridization throughout the germinal epithelium,
but there are some regional differences: expression of PIAS1 is higher near the central
region associated with round spermatids and PIASxα transcript is more abundant in the
peripheral layers of cells such as Sertoli cells, spermatogonia and early spermatocytes (Tan
et al. 2002). mRNA levels of PIAS1, PIASxα and PIASxβ in mouse testis increase during
sexual development, which is consistent with the high expression in the developing
spermatogenic cells (Tan et al. 2000 and 2002).
In contrast to PIAS1, PIASxα  and PIASy, PIAS3 mRNA is widely expressed in
various human tissues (Chung et al. 1997). Similarly, expression of KChAP/PIAS3β is
detected by northern blotting in a variety of tissues with especially high levels in lung and
kidney (Wible et al. 1998). In addition to adult tissues, PIAS proteins are expressed during
the embryonic development. Expression of PIASγ (a mouse homologue of human PIASy),
PIAS3 and GBP is detected in mouse embryos by RT-PCR as early as on embryonic day
7.5 (Sturm et al. 2000), and northern blot analysis of whole embryos reveals the presence
of mouse Miz1 transcripts from embryonic day 9.5 onwards (Wu et al. 1997).
The factors regulating PIAS protein levels are unclear at the moment, but
androgens have been shown to induce the expression of PIAS3 mRNA in LNCaP prostate
carcinoma cells (Junicho et al. 2000). Estrogens induce the accumulation of PIAS3 mRNA
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in multiple myeloma (MM) cells and increase the physical association of PIAS3 with
Stat3, which is suggested to represent a possible mechanism for estrogen-mediated
inhibition of IL-6-inducible MM cell proliferation (Wang et al. 2001b). Interestingly,
downregulation or upregulation of PIAS protein expression that correlates with increased
or decreased STAT activity, respectively, has been associated with many distinct clinical
conditions, such as anaplastic lymphoma kinase-positive T/null-cell lymphoma, acute
hepatic failure and cystic fibrosis (Kamohara et al. 2000, Kelley and Elmer 2000, Zhang et
al. 2002), as well as with physiological processes such as macrophage maturation (Coccia
et al. 2002). Down-regulation of PIASy expression has also been detected in association
with stage progression in chronic myeloid leukemia (Ohmine et al. 2001), and GBP/PIAS1
is down-regulated in RAS-transformed cells (Zuber et al. 2000).
1.4. PIAS proteins in cytokine-signaling pathway
STAT proteins are transcription factors that are activated by various cytokines (Leonard
and O'Shea 1998, Ihle 2001). Binding of the cytokine to its cell surface receptor results in
docking of STAT proteins to the receptor and tyrosine phosphorylation of STATs.
Phosphorylated STATs form dimers and translocate to the nucleus where they bind to the
promoter regions of their target genes and induce transcription (Leonard and O'Shea 1998).
PIAS1 interacts with Stat1 and inhibits transcriptional activation by blocking the DNA-
binding activity of Stat1 (Liu et al. 1998). This interaction is specific, since PIAS1 is not
able to associate with other STAT proteins (Liu et al. 1998). Likewise, PIAS3 binds
selectively to Stat3 and inhibits its DNA-binding and transcriptional activities (Chung et al.
1997). PIASy has also been shown to interact with and repress the transcriptional activity
of Stat1, but in contrast to PIAS1, without blocking the Stat1 DNA-binding activity (Liu et
al. 2001).
The association of Stat1 and Stat3 with PIAS1 and PIAS3, respectively, is detected
only when STAT proteins are activated by ligands (Chung et al. 1997, Liu et al. 1998).
Tyrosine phosphorylation of Stat1 is required for the interaction between Stat1 and PIAS1
in vivo (Liu et al. 1998). A separate study demonstrated that the dimerization of Stat1 is
crucial for Stat1-PIAS1 interaction, since PIAS1 is able to bind a Stat1 dimer, but not a
tyrosine-phosphorylated or unphosphorylated Stat1 monomer (Liao et al. 2000). The nature
of Stat1-PIAS1 interaction has been further defined by Mowen and colleagues, who found
that Stat1 dimers are methylated and that methylation prevents PIAS1 from binding to the
Stat1 dimer (Mowen et al. 2001). The importance of PIAS proteins in STAT-mediated
signaling is supported by the finding that the amounts Drosophila PIAS protein (dPIAS)
and STAT protein (STAT92E) have to be correctly balanced for the normal blood cell and
eye development to occur (Betz et al. 2001).
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1.5. Other interaction partners and functions of PIAS proteins
During the last few years, PIAS proteins have been reported to interact with various
proteins distinct from their original interaction partners, and different functions have been
suggested for the PIAS proteins (Table 1). ARIP3/PIASxα associates with DJ-1, a protein
connected to male rat infertility (Takahashi et al. 2001a). Since ARIP3/PIASxα is able to
repress AR-dependent transcription, DJ-1 was suggested to function as a positive regulator
of AR by impairing the binding of ARIP3/PIASxα to the receptor (Takahashi et al. 2001a).
ARIP3/PIASxα was also found to interact with the p67 isoform of mouse disabled 2
(mDab2) in differentiating F9 cells (Cho et al. 2000). The function of mDab2 is not clear,
but it has been suggested to play a role in signal transduction. In addition to interaction
with Stat3, PIAS3 has been found to bind to many different proteins in yeast two-hybrid
screens. The zinc finger protein Gfi-1 interacts with PIAS3 and enhances Stat3 signaling
by blocking the repressive activity of PIAS3 (Rödel et al. 2000). PIAS3 also associates
with and represses the transcriptional activity of the microphthalmia transcription factor
(MITF) that plays a role in mast cell and melanocyte development (Levy et al. 2002).
Zentner et al. (2001) demonstrated that PIAS3 binds to high mobility group protein HMGI-
C and corepresses GR and Stat3 signaling pathways with HMGI-C in salivary epithelial
cells. PIAS1 was recently reported to be a binding partner of CRP2 (cysteine- and glycine-
rich protein 2) (Weiskirchen et al. 2001).
Both PIAS1 and PIASy have been found to interact with p53 tumor suppressor
protein in yeast two-hybrid assays (Nelson et al. 2001, Megidish et al. 2002). In contrast to
PIASy that inhibits p53-dependent transactivation (Nelson et al. 2001), PIAS1 is capable
of activating p53-mediated gene expression in variety of cell lines (Megidish et al. 2002).
In line with the ability of PIAS1 to enhance the transcriptional activity of the proapoptotic
protein p53, PIAS proteins have been demonstrated to possess proapoptotic activity (Liu
and Shuai 2001). PIAS1 is able to induce apoptosis through activation of c-Jun N-terminal
kinase (JNK), and the proapoptotic function of PIAS1 is independent of the inhibitory
activity of PIAS1 in STAT-mediated gene activation (Liu and Shuai 2001).
KChAP/PIAS3β that functions as a chaperone for specific Kv channels, is also able to
induce K+ efflux and apoptosis in prostate cancer cells (Wible et al. 1998, Kuryshev et al.
2000).
An important role of PIAS proteins in chromosome organization was demonstrated
by studies showing that Su(var)2-10 locus in the Drosophila genome encoding a PIAS
protein is required for proper chromosome structure and chromosome inheritance (Hari et
al. 2001). Further evidence for the role of PIAS proteins in chromosome organization is
offered by Strunnikov et al. (2001), who showed that defects in chromosome condensation
in S. cerevisiae caused by the loss of SMT4 gene are bypassed when the SIZ1 gene
encoding a yeast homologue of mammalian PIAS proteins is overexpressed. This finding
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links PIAS proteins to SUMO-1 modification processes, since SMT encodes an
evolutionarily conserved protease exhibiting SUMO-cleaving isopeptidase activity.
Table 1. The interaction partners of PIAS proteins
PIAS protein
Interaction partner  in
the original yeast
two-hybrid screen other interactions
ARIP3/PIASxα AR (Moilanen et al. 1999) GR, PR, ER
DJ-1
mDab2
p73
Kotaja et al. 2000
Takahashi et al. 2001a
Cho et al. 2000
Minty et al. 2000
Miz1/PIASxβ Msx2 (Wu et al. 1997) AR, GR, PR, ER
p73
Kotaja et al. 2000
Minty et al. 2000
PIAS1 Stat1 (Liu et al. 1998) AR
CRP2
p53
TTF-1
Tan et al. 2000
Weiskirchen et al. 2001
Megidish et al. 2002
Missero et al. 2001
GBP Gu/RNA helicase II
(Valdez et al. 1997)
PIAS3 Stat3
AR
Gfi-1
MITF
HMGI-C
TTF-1
Chung et al. 1997
Junicho et al. 2000
Rödel et al. 2000
Levy et al. 2002
Zentner et al. 2001
Missero et al. 2001
KChAP Kvβ1.2 (Wible et al. 1998)
PIASy Stat1
AR
p53
LEF1
Liu et al. 2001
Gross et al. 2001
Nelson et al. 2001
Sachdev et al. 2001
2. STEROID RECEPTOR-MEDIATED SIGNALING
Living cells have to respond to a high number of signals that they receive constantly from
their environment. Signaling molecules can be secreted by distant endocrine organs and
transported to target cells via circulation (endocrine signaling). On the other hand, signals
can be produced by surrounding cells (paracrine signaling) or by the target cell itself
(autocrine signaling). Many kinds of signaling molecules, such as lipid-soluble hormones,
small peptides, polypeptides and lipids, exist. Signaling molecules are detected by
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receptors located either on the cell surface or inside the cell. Binding of a ligand to a cell
surface receptor usually activates a cascade of protein phosphorylation events finally
leading to activation of transcription factors that can induce transcription of target genes.
Nuclear receptors, in turn, have lipid-soluble ligands that can penetrate through the cell
membrane and bind to their cognate intracellular receptors. Steroid hormone receptors
belong to the nuclear receptor superfamily that also include receptors for thyroid
hormones, vitamin D, and retinoids, and thus regulate a broad range of functions connected
to growth, development and homeostasis. These receptors are ligand-regulated sequence-
specific transcription factors that bind to specific hormone response elements usually
located at promoter regions of their target genes, and thereby regulate transcription. In
addition to the receptors and general transcription machinery, many other coregulator
proteins are involved in the regulation of transcription. These coactivators and corepressors
bind to receptors or other coregulators, and they either enhance or repress receptor-
mediated transcription.
2.1. General transcription machinery
Promoters of mRNA-encoding genes contain three types of DNA elements. Basal promoter
elements such as the TATA-box and the initiator motif (Inr) are located near the start site
of transcription and bind proteins belonging to the general transcription machinery
(Goodrich et al. 1996). Promoter proximal elements located upstream of the start site, and
distal enhancer elements that can be located many thousands of base pairs from the start
site, bind sequence-specific transcription factors. General transcription machinery
containing RNA polymerase II and general transcription factors (GTFs) is sufficient to
promote basal gene transcription in vitro. However, sequence-specific transcription factors
as well as numerous different coregulator proteins, such as those with chromatin
remodeling activities, are required for efficient transcription and specific regulation of gene
expression in vivo (Orphanides et al. 1996, Woychik and Hampsey 2002).
Genes encoding mRNAs are transcribed by RNA polymerase II (RNAP II).
General transcription factors needed for RNAP II-mediated basal transcription include
TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH (Orphanides et al. 1996, Woychik and
Hampsey 2002). TFIID is composed of TATA-binding protein (TBP) and TBP-associated
factors (TAFs). The TBP subunit of TFIID binds to TATA box, which is a DNA element
located 25-30 bp upstream of the transcription start site. The binding is followed by the
recruitment of TFIIB, which, in turn, binds RNAP II and associated TFIIF. The
preinitiation complex (PIC) is complete after the entry of TFIIE and TFIIH (Orphanides et
al. 1996, Woychik and Hampsey 2002). TFIIH contains a kinase subunit that
phosphorylates the C-terminal domain (CTD) of the largest subunit of RNAP II (Lu et al.
1992, Serizawa et al. 1992). The phosphorylation of RNAP II after initiation of
16
transcription is crucial for gene expression, since this modification is required for
progression of transcription into the elongation phase (Dahmus 1996).
2.2. Nuclear receptor superfamily
The nuclear receptor superfamily comprises a large family of proteins (49 genes in the
human genome), including the receptors for steroid hormones (androgens, estrogens,
progestins, mineralocorticoids and glucocorticoids), retinoids, vitamin D and thyroid
hormones (Beato et al. 1995, Mangelsdorf et al. 1995, Aranda and Pascual 2001). In
addition, the superfamily includes so-called orphan receptors that share a similar structure
with other receptors, but they are not activated by ligands, or their ligands are still
unidentified (Giguere 1999). Identification of ligands for the orphan receptors has been a
subject for intense studies, and novel ligands, both natural and synthetic compounds, have
been characterized; PPAR (peroxisome proliferator activated receptor) is activated by
prostaglandins and unsaturated fatty acids, PXR (pregnane X receptor) by pregnanes, CAR
(constitutive androstane receptor) by androstanes, LXR (liver X receptor) by oxysterols,
and FXR (farnesoid X receptor) by bile acids (Giguere 1999).
Fig. 3. Modular structure of nuclear receptors. NTD, the N-terminal transactivation domain; DBD, the DNA-
binding domain; H, the hinge region; LBD, the ligand-binding domain. The main functions of each domain
are shown. The numbers depict the number of amino acid residues in the four domains in different nuclear
receptors.
Nuclear receptors share a conserved modular structure (Fig. 3). The three major
functional domains are (i) the N-terminal transactivation domain (NTD), (ii) the DNA-
binding domain (DBD), and (iii) the C-terminal ligand-binding domain (LBD). The short
nonconserved region between the DBD and the LBD is called the hinge region. The most
variable region of nuclear receptors both in sequence and size is the NTD. The three-
dimensional structure of this domain has not been resolved. Most of the nuclear receptors,
such as AR and glucocorticoid receptor (GR), have a ligand-independent transcriptional
activation function (AF1) in their NTD (Hollenberg and Evans 1988, Tora et al. 1989,
Simental et al. 1991). The NTD has been suggested to function by binding general
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transcription factors (Beato and Sanchez-Pacheco 1996, Ford et al. 1997) and coregulator
proteins (Ikonen et al. 1997, Onate et al. 1998, Alen et al. 1999, Bevan et al. 1999,
Hittelman et al. 1999, Ma et al. 1999, Wallberg et al. 1999). In the case of AR, the NTD
also participates in intramolecular interactions with the LBD of the receptor (Kraus et al.
1995, Ikonen et al. 1997).
The DBD located in the central part of the receptor is the most conserved region
among nuclear receptors. The three-dimensional structures of the DBD of many nuclear
receptors have been resolved by nuclear magnetic resonance or crystallographic studies
(Härd et al. 1990, Schwabe et al. 1990 and 1993, Luisi et al. 1991). The DBD harbors two
zinc fingers that are formed when four cysteine residues coordinately bind a zinc ion in
each of the two motifs. The first zinc finger is critical for specific DNA contacts, and the
second zinc finger interacts with the DNA phosphate backbone and is involved in receptor
dimerization (Freedman 1992, Quigley et al. 1995). In addition to DNA binding and
dimerization, the DBD of nuclear receptors is involved in interactions with coregulators
(Moilanen et al. 1998a, 1998b and 1999, Blanco et al. 1998, Puigserver et al. 1998), and it
is also required for cross-talk with other transcription factors such as NF-κB and AP-1
(Schüle et al. 1990, Ray and Prefontaine 1994, Aarnisalo et al. 1999).
The LBD contains the ligand-binding pocket, activation function 2 (AF2) and
dimerization surface. The crystal structures of various nuclear receptors have revealed a
common structure with 12 α helices and one β turn arranged as an antiparallel α-helical
sandwich in a three-layer structure (Bourguet et al. 1995, Renaud et al. 1995, Wagner et al.
1995, Wurtz et al. 1996, Brzozowski et al. 1997, Nolte et al. 1998, Williams and Sigler
1998). Upon binding of the ligand, specific α helices are repositioned leading to sealing of
the ligand-binding cavity with helix H12. The ligand-induced repositioning of H12
provides the surface(s) for coactivator interactions and generates the active AF2. The
crystal structure of estrogen receptor α ( ERα) LBD complexed with the antagonist
raloxifen shows that the antagonist induces a conformation distinct from the agonist-
induced conformation; in the antagonist-induced conformation, H12 is placed in an
"antagonist position"  (Brzozowski et al. 1997). This conformation blocks the surface
formed by helices H12, H3, H4 and H5 normally used for the binding of an LXXLL motif
of TIF2/GRIP1, a member of SRC family of nuclear receptor coactivators (Shiau et al.
1998). The crystal structure of PPARα  LBD bound to an antagonist and a SMRT co-
repressor motif shows that the antagonist-bound receptor adopts a conformation, which
facilitates the binding of corepressors (Xu et al. 2002).
2.3. Mode of steroid receptor action
In an inactive state, steroid receptors are associated with large multiprotein complexes,
including heat shock proteins Hsp90, Hsp56, Hsp70 and p23 (Beato et al. 1996, Pratt and
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Toft 1997). In these complexes, the receptors are maintained in a high-affinity ligand
binding form. Binding of a ligand induces a conformational change in the receptor
structure that leads to dissociation of heat shock proteins and allows dimerization of the
receptors (Fig. 4, Pratt and Toft 1997, Moras and Gronemeyer 1998). To activate gene
transcription, nuclear receptors have to be transported to the nucleus. The cellular
localization prior to ligand binding varies among different steroid receptors. GR is
predominantly located in the cytoplasm, and ligand induces its nuclear transport (Picard
and Yamamoto 1987, Sackey et al. 1996). In contrast to GR, unliganded ER and
progesterone receptor (PR) seem to be mostly nuclear (Htun et al. 1999, Lim et al. 1999).
AR has been reported to be both nuclear and cytoplasmic depending on the experimental
conditions used (Jenster et al. 1993, Zhou et al. 1994, Karvonen et al. 1997).
Fig. 4. Mode of steroid receptor action. R, steroid receptor; H, hormone; hsp, heat shock protein; HRE,
hormone response element; PIC, preinitiation complex. Upon hormone binding, receptors dimerize, bind to
the hormone response element and thereby regulate the gene transcription. Coregulator proteins bind to the
receptor dimer and modulate steroid receptor-dependent transcription.
Nuclear receptors are grouped into four classes according to their ligand-binding,
DNA-binding and dimerization properties (Mangelsdorf et al. 1995). Class I nuclear
receptors including steroid receptors form homodimers, but some members of this class are
also suggested to form heterodimers (Trapp et al. 1994, Liu et al. 1995, Cowley et al. 1997,
Lee et al. 1999). Class II receptors, such as vitamin D receptor (VDR), retinoic acid
receptor (RAR), PPARs and thyroid hormone receptor (TR), heterodimerize with retinoid
X receptor (RXR). Class III contains some orphan receptors that bind DNA as
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homodimers, and class IV orphan receptors bind DNA as monomers (Mangelsdorf et al.
1995). AR, GR, PR and mineralocorticoid receptor (MR) homodimers are capable of
binding to the palindromes of the sequence AGAACA separated by three nucleotides (5'-
AGAACAnnnTGTTCT-3'), whereas ER recognizes the palindromic consensus sequence
5'-AGGTCAnnnTGACCT-3'. Class II nuclear receptors bind preferentially to direct
repeats separated by one to five nucleotides (DR1-5), but they can also recognize response
elements in palindromic or inverted palindromic configurations (Glass 1994, Aranda and
Pascual 2001). In addition to the positive response elements that mediate receptor-
dependent activation of gene expression, so-called negative response elements that bind the
receptors and mediate negative regulation by the ligand have been reported (Sakai et al.
1988, Drouin et al. 1989, Zhang et al. 1997).
Most of the steroid receptors excluding ER are able to recognize the same response
element, and they also have overlapping expression patterns. This raises a question of how
the receptor specific actions are achieved in vivo. One possibility is that the binding of
other transcription factors to the same promoter region modulate the specificity of the
receptor. In addition, the promoter regions of many natural target genes of steroid
receptors, especially those of AR, contain "modified" response elements with enhanced
affinity to specific receptors (Claessens et al. 1996, Zhou et al. 1997, Schoenmakers et al.
1999 and 2000, Verrijdt et al. 2000). These findings are, however, unlikely to be the only
explanations for the specificity of target gene activation. A new aspect to the regulation of
steroid receptor-dependent transcription was introduced with the discovery of an increasing
number of coregulator proteins (Fig. 5).
2.3.1. Coactivators
Coactivators do not usually possess DNA-binding activity, but they interact with the DNA-
bound receptor or with other receptor-bound coregulators, and enhance the steroid
receptor-dependent transcription. Coactivators form large coactivator complexes, and it is
suggested that the nuclear receptor-mediated transcription requires several different protein
complexes that may act sequentially, combinatorially or in parallel (Fig. 5, Glass and
Rosenfeld 2000, Hermanson et al. 2002, McKenna and O'Malley 2002). The coactivator
complexes with histone acetyltransferase (HAT) activity promote transcription by
acetylating histone tails which is known to "loosen" nucleosome structures making genes
more accessible for transcription. The complexes with ATP-dependent chromatin-
remodeling activities also enhance transcription by opening up tightly packed chromatin.
In addition, the multiprotein TRAP/DRIP/Mediator complex interacts with both receptor
dimers and general transcription machinery and thus functions as a bridging factor between
them. Steroid receptors and coactivators have been suggested to bind to the promoters in a
cyclic fashion so that the binding of the receptor dimer is followed by the recruitment of
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different coactivator complexes, after which dissociation of proteins takes place and the
cycle is repeated (Shang et al. 2000, Burakov et al. 2002).
In addition to the above-described proteins that function as acetyltransferases,
ATPases and mediators, many other coactivators with different functions have been
reported (McKenna et al. 1999). The E3 ubiquitin-protein ligase E6-AP interacts with and
coactivates steroid receptors in a fashion that is independent of its ligase activity (Nawaz et
al. 1999a, Smith et al. 2002). The small nuclear RING finger protein SNURF that is able to
bind steroid receptors and modulate steroid receptor-dependent transcription is also a
potential ubiquitin E3 ligase (Moilanen et al. 1998a, our unpublished results). The high-
mobility group proteins 1 and 2 (HMG-1 and -2) – chromatin non-histone proteins that
bind DNA and induce bends in DNA – increase the sequence-specific DNA-binding and
transcriptional activity of steroid receptors (Boonyaratanakornkit et al. 1998). Furthermore,
the androgen receptor-interacting nuclear protein kinase (ANPK/HIPK3) is a Ser/Thr
protein kinase capable of enhancing AR-mediated transcription (Moilanen et al. 1998b).
Interestingly, the steroid receptor RNA activator (SRA) that selectively coactivates AF1 of
steroid receptors, differs from other coactivators in that the functional form of SRA is not a
protein but a RNA transcript (Lanz et al. 1999).
Fig. 5. Coactivator and corepressor complexes modulate the activity of nuclear receptors (NR). Coactivators
form distinct complexes with different functional properties: ATPase activity-containing complexes are able
to remodel chromatin, HAT-containing complexes acetylate histones and TRAP/DRIP complexes mediate
interaction between receptors and general transcription machinery. Corepressor complexes contain histone
deacetylase activities (HDAC). Double-headed arrows show the interactions between coregulators and
receptors. RNAPII: RNA polymerase II; B, E, F and H: TFIIB, TFIIE, TFIIF and TFIIH, respectively
(adapted from Glass and Rosenfeld 2000).
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Complexes with histone acetyltransferase activity
The best-characterized coactivator family, the SRC family (the p160 family), includes
SRC-1/NCoA-1 (Oñate et al. 1995, Kamei et al. 1996), GRIP1/TIF2/SRC-2 (Hong et al.
1996, Voegel et al. 1996), pCIP/TRAM-1/RAC3/ACTR/AIB-1/SRC-3 (Anzick et al. 1997,
Chen et al. 1997, Li et al. 1997, Takeshita et al. 1997, Torchia et al. 1997). The nuclear
receptor interaction domain (NID) of the SRC family members contain three LXXLL
signature motifs, where L represents leucine residue and X represents any amino acid
(Heery et al. 1997). The LXXLL motifs have a well-characterized role in the binding of the
coactivator to the LBD of the receptor (Darimont et al. 1998, Shiau et al. 1998). The
LXXLL-LBD interaction is ligand-dependent and in the absence of ligand, or in the
presence of antagonist, the surface for the binding of the LXXLL peptide is blocked (Shiau
et al. 1998). The NID that is located in the central part of SRC proteins is not, however, the
only region binding to nuclear receptors, since the C-terminal region of SRC-2/GRIP1 has
been shown to mediate the binding to the AF1 of AR (Alen et al. 1999, Ma et al. 1999).
The physiological importance of the SRC proteins has been demonstrated by gene
targeting in mice (Xu et al. 1998 and 2000). Disruption of the SRC-1 gene caused partial
resistance to steroid hormones (Xu et al. 1998). The expression of another family member,
SRC-2/GRIP1, was increased in the SRC-1 null mice suggesting that SRC-2/GRIP1 might
compensate partially for the loss of SRC-1 (Xu et al. 1998). Disruption of the SRC-3 gene
had more severe effects resulting in dwarfism, delayed puberty, reduced female
reproductive function, and blunted mammary gland development (Xu et al. 2000). SRC-1
and SRC-3 harbor HAT activities (Chen et al. 1997, Spencer et al. 1997), but a more
important function of these proteins seems to be the recruitment of other HAT coactivators
to the promoter-bound receptor dimer. The SRC family members interact with CBP
(CREB-binding protein) and a highly related p300 (Kamei et al. 1996, Torchia et al. 1997,
Voegel et al. 1998). CBP and p300 have been demonstrated to play important roles in the
nuclear receptor function (Chakravarti et al. 1996, Hanstein et al. 1996, Kamei et al. 1996,
Yao et al. 1998). CBP/p300 exhibits a strong HAT activity (Ogryzko et al. 1996), and it
also recruits another HAT activity, P/CAF, to the coactivator complex (Blanco et al. 1998).
The SRC family members interact also with other enzymatic activities, such as the arginine
methyltransferase CARM1 (Chen et al. 1999a).
Complexes with ATP-dependent chromatin remodeling activity
The yeast SWI/SNF complex possesses ATP-dependent chromatin remodeling activity,
and it is able to cause local changes in chromatin structure and thus facilitate the binding of
sequence-specific transcription factors to the nucleosomal DNA (McKenna et al. 1999,
Glass and Rosenfeld 2000). The ATPase activity-containing component of the yeast
SWI/SNF complex is encoded by swi2 and snf2 genes. Importance of these factors in
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nuclear receptor function has been demonstrated. Mammalian homologues of yeast SWI2
and SNF2, hBRM and BRG-1, interact with ER in a ligand-dependent manner (Ichinose et
al. 1997). In addition, the activity of GR  in yeast requires SWI/SNF factors (Yoshinaga et
al. 1992), and interaction with BRG-1-containing complexes is required for GR function
on a stably integrated MMTV promoter (Fryer and Archer 1998).
TRAP/DRIP complexes
TRAP (TR-associated protein) and DRIP (VDR-interacting protein) complexes are
homologous multiprotein complexes that were originally found to associate with TR or
VDR, respectively (Fondell et al. 1996, Rachez et al. 1998). TRAP and DRIP complexes
are able to enhance transcriptional activity of TR and VDR in cell-free systems, and DRIP
complex stimulates hormone-dependent transactivation by VDR also on chromatin
templates (Fondell et al. 1996, Rachez et al. 1998, Rachez et al. 1999). Many components
of the TRAP/DRIP complex are present in a mammalian complex corresponding to the
yeast mediator, and the TRAP/DRIP complex also shares similar components with SMCC
(SRB/mediator coactivator complex), NAT (negative regulator of activated transcription),
and CRSP (cofactor required for Sp1 activation) complexes (Hampsey and Reinberg 1999,
Glass and Rosenfeld 2000). The TRAP/DRIP complex has been suggested to function by
mediating the interaction between nuclear receptors and general transcription machinery
(McKenna et al. 1999, Glass and Rosenfeld 2000). TRAP220 protein in the TRAP/DRIP
complex mediates the interaction with the nuclear receptors by binding directly to the LBD
of the receptors (Yuan et al. 1998). TRAP220 is essential for embryonic development since
mice lacking the trap220 gene die during an early gestational stage (Ito et al. 2000).
Primary embryonic fibroblasts of TRAP220 null mutants show impaired TR function (Ito
et al. 2000).
2.3.2. Corepressors
Class II NRs can bind DNA in the absence of a ligand and repress transcription of the
target genes. Repression may be passive resulting from competition for DNA binding sites
with active transcription factors or formation of inactive heterodimers with other receptors.
On the other hand, unliganded NRs bound to DNA may also actively repress the initiation
of transcription, either directly or indirectly with the help of other factors (McKenna et al.
1999, Glass and Rosenfeld 2000). N-CoR (NR corepressor) and highly related SMRT
(silencing mediator for RAR and TR) are corepressor proteins that bind unliganded NRs
and inhibit transcription (Chen and Evans 1995, Hörlein et al. 1995). N-CoR and SMRT
interact with Sin3 protein, which, in turn, recruits multiprotein complexes containing
histone deacetylase (HDAC) activities (Heinzel et al. 1997, Nagy et al. 1997). By this
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means, repression of gene transcription by NRs can be mediated through recruitment of
HDAC complexes and deacetylation of histones.
The steroid receptors do not show DNA-binding activity in the absence of
hormone. However, an antagonist-bound steroid receptor is able to dimerize and bind to
DNA, but the resultant receptor dimer is unable to stimulate transcription. SMRT and N-
CoR have been shown to interact with antagonist-bound steroid receptors, and the
recruitment of these corepressors seems to be essential for the activity of ER and PR
antagonists (Jackson et al. 1997, Smith et al. 1997, Wagner et al. 1998, Zhang et al. 1998).
Additionally, many different proteins have been reported to interact with ligand-activated
NRs and negatively regulate their transcriptional activity. For example, RIP140 is able to
repress transcriptional activity of various NRs (Treuter et al. 1998, Subramaniam et al.
1999), and the members of PIAS protein family can either enhance or repress steroid
receptor-dependent transcription depending the cell line and the promoter studied (Kotaja
et al. 2000, Tan et al. 2000, Gross et al. 2001).
2.4. Androgen receptor
Androgens play a crucial role in the male sexual development and in the maintenance of
the male phenotype. Two main physiological androgens are testosterone and 5α-
dihydrotestosterone. The latter one is converted from testosterone by the 5α-reductase
enzyme. The effects of androgens are mediated by AR that was cloned and sequenced in
1988 (Chang et al. 1988, Lubahn et al. 1988). The AR gene is located in X chromosome.
The AR protein is expressed in a wide variety of genital and nongenital tissues (Quigley et
al. 1995). A number of AR target genes have been identified, but the physiological
functions of some of these genes remain to be established. Examples of the AR responsive
genes include probasin, C3(1) gene of prostatic binding protein, prostate-specific antigen
(PSA), human glandular kallikrein-1 (hKLK2) and sex-limited protein (Slp) (Claessens et
al. 1989, Adler et al. 1992, Murtha et al. 1993, Rennie et al. 1993, Cleutjens et al. 1996).
Androgens have also been reported to regulate the expressions of some cell cycle
regulatory proteins such as the cyclin-dependent kinase 2 (CDK2), the CDK4, and the
cyclin-dependent kinase inhibitors p16 and p21 (Lu et al. 1997 and 1999).
Various diseases are associated with defects in the function of AR protein, and a
wide spectrum AR gene mutations have been characterized (Quigley et al. 1995). Diseases
associated with the mutated AR include androgen insensitivity syndrome (AIS), prostate
cancer and Kennedy's disease. Complete absence of AR function results in the complete
AIS (also termed complete testicular feminization) with a failure in the development of
both the internal and external male structures. Less severe mutations in AR lead to a range
of intermediate phenotypes. The AR mutations that cause AIS can be single point
mutations, larger deletions or insertions that affect binding of ligand or DNA, create
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premature stop codons or alter mRNA splicing (Quigley et al. 1995, McPhaul 1999).
Kennedy's disease that is also known as spinal and bulbar muscular atrophy (SBMA), is an
X-linked motor neuron disorder associated with an increased length of the polymorphic
glutamine repeat (CAG repeat) in the N terminus of AR (Quigley et al. 1995). Androgens
and AR have an important role in the development of prostate, and thus a lot of attention
has been focused on their potential role in the development and progression of prostate
cancer – the most common malignancy of men in many industrialized countries. Blocking
of androgen action is often used as a treatment for inoperable prostate cancers.
Unfortunately, most of the prostate cancers become eventually resistant to the androgen
deprivation therapy. Hence, mutations or amplifications of the AR gene may be involved
in the progression of the disease (Lopez-Otin and Diamandis 1998).
3. COVALENT MODIFICATIONS IN NUCLEAR RECEPTOR FUNCTION
Expression of proteins can be regulated practically at any step in a pathway starting from
initiation of gene transcription and leading to synthesis of a functional protein (Orphanides
and Reinberg 2002). Even though the initiation of transcription is a crucial regulatory step,
also mRNA processing, mRNA transport, translation and folding of proteins are subjected
to important regulation. The activities of proteins are further controlled by regulating their
localization and rate of turnover. In addition, posttranslational modifications serve a quick
way to modulate the functions of proteins. Proteins are subjected to various covalent
modifications, such as glycosylation, acetylation, methylation, phosphorylation, ADP-
ribosylation, ubiquitination or sumoylation. Covalent modifications also regulate nuclear
receptor-dependent transcription by modifying activities of transcription factors and by
remodeling the chromatin structural proteins.
3.1. Modification of structural proteins of chromatin
DNA is packed into a hierarchy of structures, the basic repeating structural unit being the
nucleosome. The nucleosome core consists of a histone octamer (H3-H4 tetramer and two
H2A-H2B dimers) wrapped with 146 bp of DNA. Histone H1 binds to the core histones
and to the linker DNA. Because of the tight packing, genes and their promoter regions are
not accessible to the binding of transcription factors. Thus, chromatin structure has to be
loosened to enable efficient transcription. The N-terminal tails of histones are susceptible
to many covalent modifications, such as acetylation, methylation, phosphorylation and
ubiquitination, and the modifications have a key role in altering chromatin structure and
function (Spencer and Davie 1999). Acetylation of the core histones is connected to
transcriptionally active chromatin, whereas transcriptionally silent genes are typically
hypoacetylated (Struhl 1998). Acetylation of the specific lysine residues of histone tails
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loosens the nucleosome packing and facilitates the interaction of transcription factors with
nucleosomal DNA (Struhl 1998, Spencer and Davie 1999). Mechanistic connection
between histone acetylation and gene expression has been clarified by the finding that
some coactivators, such as SRC-1, SRC-3, CBP/p300 and P/CAF that are recruited to the
promoter region by nuclear receptors, possess histone acetyltransferase activity (Ogryzko
et al. 1996, Chen et al. 1997, Spencer et al. 1997, Blanco et al. 1998, McKenna et al. 1999,
Hermanson et al. 2002). Corepressor complexes, on the other hand, contain histone
deacetylases that repress transcription by deacetylating histone tails (Struhl 1998,
McKenna et al. 1999).
DNA methylation has a well-characterized role in the silencing of gene expression
(Bird and Wolffe 1999), but methylation of proteins also contributes to chromatin
remodeling and gene transcription (Stallcup 2001). Like acetylation, methylation of the
core histone tails is associated with the active chromatin (Stallcup 2001). Interestingly, two
proteins with methyltransferase activities, coactivator-associated arginine
methyltransferase 1 (CARM1) and protein arginine methyltransferase 1 (PRMT1), have
been found to interact with the nuclear receptor coactivator GRIP1 and cooperate with
GRIP1 in the nuclear receptor-dependent transcription (Chen et al. 1999a, Koh et al. 2000).
CARM1 methylates specific arginine residues of histone H3 (Schurter et al. 2001), and
PRMT1 preferentially modifies H4 (Chen et al. 1999a, Strahl et al. 2001). The core
histones and histone H1 are phosphorylated at specific serine and threonine residues, and
these modifications have also been shown to be involved in the regulation of transcription
(Spencer and Davie 1999).
3.2. Modification of transcription factors
In addition to modifying chromatin structure, covalent modifications participate in the
regulation of transcription by modulating activities of proteins involved in transcription,
such as RNAP II, sequence specific transcription factors and coregulators. Ligands play an
important role in regulating the function of the steroid receptors, but some receptors appear
also to be activated in a ligand-independent fashion (Beato et al. 1996). Both ligand-
dependent and ligand-independent activities of the receptors are modulated by cross-talk
with other cellular signaling pathways that start from the cell surface receptors and are
carried to the nucleus via phosphorylation cascades mediated by various kinases (Weigel
1996, Weigel and Zhang 1998). Phosphorylation has been demonstrated to regulate many
functions of NRs, including transcriptional activity, DNA binding, binding to coactivators,
dimerization and stability (Arnold et al. 1995, Kato et al. 1995, Chen et al. 1999b,
Tremblay et al. 1999, Lange et al. 2000). In addition to the NRs, coregulator proteins, such
as SRC family members and CBP/p300, are phosphorylated, and the modification
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modulates their function as transcriptional coregulators (Font de Mora and Brown 2000,
Rowan et al. 2000, Lopez et al. 2001).
Acetylation and methylation have not been studied as extensively as
phosphorylation, but transcription factors have also been reported to be modulated by these
modifications. The coactivators CBP/p300 and P/CAF are able to acetylate AR, and also
ERα is subject to acetylation by CBP/p300 (Fu et al. 2000, Wang et al. 2001a).
Interestingly, mutation of the AR acetylation site abrogates the ligand-dependent function
of the receptor and coactivation by coactivators, correlating with increased binding to N-
CoR corepressor (Fu et al. 2000 and 2002). Acetylation of ACTR/SRC-3 by CBP/p300
disrupts the association of ACTR with the NRs, suggesting that acetylation of coregulators
acts as a regulatory mechanism in hormonal signaling (Chen et al. 1999c). Regulation of
transcription factors by methylation is supported by the study demonstrating that Stat1 is
methylated by PRMT1 and that methylation is required for transcriptional activation
(Mowen et al. 2001). Interestingly, inhibition of methylation facilitates the binding of
PIAS1 to Stat1, leading to decreased DNA binding and inhibition of STAT signaling
(Mowen et al. 2001). In addition, the coactivator CBP/p300 is a target for methylation by
CARM1, and methylation blocks the interaction of CBP/p300 with the transcription factor
CREB (cAMP responsive element binding protein) (Xu et al. 2001)
3.2.1. Ubiquitination and proteasome-mediated degradation
Ubiquitin is a small (8.5 kDa) protein that can be covalently attached to lysine residues of
target proteins (Weissman 2001). Target protein can be modified at one or more lysines
with a single ubiquitin (monoubiquitination), or with ubiquitin chains formed by
attachment of ubiquitin molecules to lysine residues of the previous ubiquitins
(polyubiquitination) (Hicke 2001, Weissman 2001). Ubiquitination is mediated by at least
three types of enzymes (Weissman 2001). First, the E1 ubiquitin-activating enzyme forms
a thiolester bond with ubiquitin. Subsequently, ubiquitin is transferred to the E2 ubiquitin-
conjugating enzyme, and finally, the E3 ubiquitin ligases mediate the transfer of ubiquitin
to the lysine residue of the target protein. There are two major families of ubiquitin E3
enzymes: the HECT (homologous to E6-AP carboxyl terminus) domain E3s form
thiolester intermediates with ubiquitin, whereas the RING finger E3s mediate the transfer
of ubiquitin to substrate without thiolester bond formation (Weissman 2001).
The specificity of the action of ubiquitination on target proteins is generated largely
by the enzymes that recognize the substrates, and also by the types of ubiquitin conjugates
formed (Chan and Hill 2001, Weissman 2001). The best-characterized function of protein
ubiquitination is the targeting of proteins to proteasome-mediated degradation
(Hochstrasser 1996). Interestingly, monoubiquitination does not lead to protein
degradation, but attachment of four or more ubiquitins does (Thrower et al. 2000). In
addition to protein degradation, polyubiquitination controls other cellular functions, such
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as regulation of translation and DNA repair (Weissman 2001). The choice of lysine in
ubiquitin sequence that is used for multiubiquitin chain formation affects the fate of target
protein; polyubiquitin chains linked through lysine 48 are potent targeting signals for
degradation, whereas lysine 63 linkages seem to be important for DNA repair (Hicke 2001,
Weissman 2001). Monoubiquitination, on the other hand, has been demonstrated to
regulate totally different events, such as functions of histones, endocytosis of proteins and
budding of retroviruses (Hicke 2001).
Transcription factors are targets for ubiquitin-mediated proteasomal degradation,
and there is positive correlation between the potency and instability of a given
transcriptional activator (Thomas and Tyers 2000, Salghetti et al. 2001). Involvement of
ubiquitination in transcriptional regulation is supported by a study that identified a
ubiquitin-protein ligase subunit within the CCR4-NOT transcription repressor complex
(Albert et al. 2002). Interestingly, ubiquitination was recently shown to mediate cofactor
exchange on DNA-bound LIM homeodomain transcription factors (Ostendorff et al. 2002).
Steroid receptors are also targets for ubiquitin-dependent degradation (Nawaz et al. 1999b,
Wallace and Cidlowski 2001). Stabilization of GR by proteasome inhibitor MG132 results
in enhanced transcriptional activity (Wallace and Cidlowski 2001, Deroo et al. 2002). In
contrast to GR, treatment of cells with MG132 was shown to inhibit the activity of ERα,
suggesting that ubiquitination and proteasome function is required for ERα-mediated
transcription (Lonard et al. 2000). Since steroid receptor coregulators are also targets  for
degradation via the proteasome,  the proteasome-dependent degradation may play an
important regulatory role in the receptor and coactivator turnover and coactivator complex
exchange in the steroid receptor-mediated transcription (Lonard et al. 2000, Hermanson et
al. 2002).
4. SUMO-1 MODIFICATION
SUMO modification (sumoylation) is a recently characterized covalent modification that
leads to attachment of SUMO (small ubiquitin-related modifier) protein to specific lysine
residues of target proteins (Melchior 2000, Yeh et al. 2000). SUMO is a small polypeptide
that shows a significant structural homology to ubiquitin. SUMO and ubiquitin are only
18% identical, but they share a similar three-dimensional structure, the ββαββαβ
ubiquitin-fold (Fig. 6, Bayer et al. 1998, Jin et al. 2001). Members of the SUMO protein
family are present in protozoa, yeast, plants and metazoa. SUMO family in metazoa consist
of three related proteins, SUMO-1 (also known as PIC1, Ubl1, sentrin, GMP1, Smt3c or
hSmt3), SUMO-2 (sentrin2 or Smt3a) and SUMO-3 (sentrin3 or Smt3b) (Melchior 2000).
SUMO-2 and SUMO-3 are 95% identical, but SUMO-1 shares only about 50% sequence
identity with SUMO-2/3. The least conserved region of SUMO proteins is the N terminus.
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It is highly flexible, protrudes from the core of the proteins, and is absent in the ubiquitin
(Bayer et al. 1998).
Both ubiquitin and SUMO have the two conserved Gly residues in their C termini
that are essential for the conjugation (Bayer et al. 1998). Before conjugation, the last four,
eleven or two amino acids of SUMO-1, -2 or -3, respectively, have to be proteolytically
cleaved to expose the Gly residues. Lysines in ubiquitin sequence that are used to generate
ubiquitin polymers are absent in SUMO-1 sequence, which is in line with the finding that
only one SUMO-1 molecule is attached to a given lysine residue of target protein. In
contrast, SUMO-2/3 is capable of forming polymers by using lysine 11 as an attachment
site for another SUMO-2/3 (Tatham et al. 2001). The corresponding lysine is not
conserved in SUMO-1, and SUMO-1 was demonstrated to be unable to form polySUMO
chains in vitro (Tatham et al. 2001). Sumoylation is mechanistically similar to
ubiquitination, but the function of sumoylation is less well understood than that of
ubiquitination. SUMO-1 and SUMO-2/3 probably have distinct regulatory roles, and
SUMO-2/3 conjugation has been suggested to play a role in the cellular response to
environmental stress (Saitoh and Hinchey 2000).
Fig. 6. Comparison of the three-dimensional structures of SUMO-1 and ubiquitin. SUMO-1 contains the
characteristic ββαββαβ ubiquitin-fold common to ubiquitin-like proteins. The Gly-Gly motif is shown at the
C terminus of the proteins. The most prominent difference between the proteins is the flexible N-terminal tail
of SUMO-1 (Melchior 2000).
4.1. Enzymes involved in SUMO modification pathway
The general mechanism of sumoylation and ubiquitination are highly related, but the
enzymes involved in the two processes are distinct (Melchior 2000). After the C-terminal
processing, SUMO is activated in an ATP-dependent reaction by formation of a thiolester
bond with the E1 enzyme. Subsequently, SUMO is transferred to the E2 SUMO
conjugating enzyme. In ubiquitination, the E3 ubiquitin ligases are required to ensure
substrate specificity (Weissman 2001), and recently, the E3 ligases for sumoylation have
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also been characterized. Like ubiquitination, sumoylation is a reversible process, and
SUMO is cleaved from target proteins by isopeptidases (Fig. 7, Melchior 2000).
Fig. 7. The SUMO modification pathway. The C-terminal amino acids have to be cleaved by C-terminal
hydrolases to expose the Gly-Gly motif for conjugation. Attachment of SUMO to lysine residues of target
proteins is catalyzed by E1, E2 and E3 enzymes related to the enzymes in ubiquitination pathway.
Sumoylation is reversible, and SUMO can be removed from target proteins by isopeptidases (adapted from
Melchior 2000).
4.1.1. E1, E2 and E3 activities
The cDNAs for the E1 enzyme activity in sumoylation pathway has been cloned from both
yeast and human. The E1 is a heterodimer composed of Aos1/SAE1/Sua1 and Uba2/SAE2
(Johnson et al. 1997, Desterro et al. 1999, Gong et al. 1999, Okuma et al. 1999). Aos1 is
homologous to the N-terminal region of the ubiquitin E1 Uba1, whereas Uba2 shares
homology with the C-terminal half of Uba1. Uba2 bears the cysteine residue required for
the formation of SUMO-E1 enzyme thiolesters, but both Uba2 and Aos1 are required for
the activation of SUMO in vitro and in vivo (Johnson et al. 1997, Desterro et al. 1999,
Gong et al. 1999). Human Aos1/Uba2 heterodimer is able to form thiolester bonds with all
members of the SUMO family in vitro, thus SUMO-1, SUMO-2 and SUMO-3 can be
activated by the same E1 enzyme (Gong et al. 1999).
In contrast to large number of E2 conjugating enzymes in ubiquitin pathway, only
one SUMO conjugating enzyme, Ubc9, has been identified (Desterro et al. 1997, Gong et
al. 1997, Johnson and Blobel 1997, Schwarz et al. 1998, Müller et al. 2001). Ubc9 is
highly conserved from yeast to human, and it shares a striking similarity with the large
family of ubiquitin-conjugating enzymes. However, the surface charge distributions of
Ubc9 and ubiquitin E2s are very different, and the Ubc9 surface involved in interaction
with SUMO-1 is highly complementary in its electrostatic potential and hydrophobicity to
the surface of SUMO-1 (Liu et al. 1999). In line with this notion, Ubc9 is specific for
SUMO and does not conjugate ubiquitin (Desterro et al. 1997, Gong et al. 1997, Johnson
and Blobel 1997, Schwarz et al. 1998). Ubc9 is capable of interacting with almost all
SUMO substrates. SUMO-1 consensus attachment sequence, ΨKXE  (Ψ  is a large
hydrophobic residue and X represents any amino acid), has been demonstrated to be a
SUMO–xxxx
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major determinant of Ubc9 binding and SUMO-1 modification (Sampson et al. 2001). The
peptides corresponding to the SUMO-1 conjugation sites of p53 and c-Jun were shown by
NMR spectroscopy to bind to a surface adjacent to the active site Cys93 of human Ubc9
(Lin et al. 2002). In addition, crystallographic analysis of a complex between mammalian
Ubc9 and the C-terminal domain of RanGAP1 revealed the structural determinants for
recognition of consensus SUMO sequence by Ubc9 (Bernier-Villamor et al. 2002).
In ubiquitination, the E3 ubiquitin ligases are needed to ensure substrate specificity
(Weissman et al. 2001). They are defined as proteins that bind specific protein substrates
and promote the transfer of ubiquitin from a thiolester intermediate to amide linkages with
protein or polyubiquitin chains (Melchior 2000). The requirement for similar SUMO E3
ligase activity was doubted in the past because, first, the SUMO E2 enzyme Ubc9 is able to
bind almost all known SUMO substrates, and second, E1 and E2 enzymes are sufficient for
sumoylation of specific substrates in vitro. However, very recently the PIAS proteins were
demonstrated to act as E3 SUMO ligases for various substrates both in yeast and in
mammalian cells (Hochstrasser 2001, Jackson 2001, Kotaja et al. 2002). Yeast PIAS
homologue Siz1 promotes SUMO conjugation to the yeast septins both in vitro and in vivo
(Johnson and Gupta, 2001, Takahashi et al. 2001b and 2001c). In addition, PIASy
stimulates sumoylation of the Wnt-responsive transcription factor LEF1, and PIAS1 and
PIASxβ act as SUMO ligases for c-Jun and p53 (Kahyo et al. 2001, Sachdev et al. 2001,
Schmidt and Müller 2002). The E3 activity of PIAS proteins is dependent on their RING
finger-like structure. Interestingly, nucleoporin RanBP2 that is not related to PIAS proteins
was also identified as a SUMO E3 ligase (Pichler et al. 2002). RanBP2 does not contain a
RING finger structure, and in contrast to PIAS proteins that are nuclear, RanBP2 is located
in nuclear pores (Pichler et al. 2002).
4.1.2. SUMO C-terminal hydrolases and isopeptidases
The C-terminal hydrolases are responsible for cleaving the C terminus of SUMO before
conjugation to target proteins (Melchior 2000, Müller et al. 2001). Sumoylation is a
reversible process, and SUMO-protein conjugates are highly susceptible to deconjugation
by isopeptidases (Melchior 2000). C-terminal hydrolases and isopeptidases are cysteine
proteases that share some homology with viral cysteine proteases, but are unrelated in
sequence to deubiquitinating enzymes (Melchior 2000, Müller et al. 2001). In yeast, two
SUMO-specific proteases, Ulp1 (ubiquitin-like protease 1) and Ulp2, have been identified
(Li and Hochstrasser 1999 and 2000). These proteases are specific for SUMO, in that they
do not cleave ubiquitinated proteins. A 30-kDa ubiquitin-related SUMO-1 hydrolase has
been isolated from bovine brain, and two human enzymes, SENP1 (sentrin-specific
protease) and SUSP1 (SUMO-1-specific protease), have been cloned (Suzuki et al. 1999,
Gong et al. 2000, Kim et al. 2000). In addition, an expressed sequence tag (EST) databank
search, based on the conserved ULP domain from yeast Ulp1, have identified additional
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homologous sequences in human, suggesting the existence of a larger family of SUMO-
specific proteases (Yeh et al. 2000). Most of the identified SUMO processing enzymes are
usually able to function as both C-terminal hydrolases and isopeptidases. The substrate
specificity of different proteases might be partly determined by their intracellular
localization; for example, Ulp2 and SENP1 are intranuclear, SUSP1 is found in the
cytoplasm and Ulp1 appears to be concentrated around the nuclear envelope (Gong et al.
2000, Kim et al. 2000, Li and Hochstrasser 2000).
4.2. SUMO target proteins and possible functions of sumoylation
Genetic studies have demonstrated that the sequences encoding E1 and E2 enzymes,
SUMO and Ulp1 protease are essential for the viability of S. cerevisiae (Dohmen et al.
1995, Seufert et al. 1995, Johnson et al. 1997, Li and Hochstrasser 1999). In contrast,
SUMO and Ubc9 in S. pombe are not essential for the viability, but inactivating mutations
of these genes cause severe defects in growth and chromosome segregation (Al-Khodairy
et al. 1995, Tanaka et al. 1999). Temperature-sensitive mutants in the S. cerevisiae genes
coding for Uba2, Ubc9 and Ulp1 also show strong cell-cycle defects, and the mutant cells
arrest predominantly at the G2/M boundary of the cell cycle (Seufert et al. 1995, Johnson
et al. 1997, Li and Hochstrasser 1999). These results suggest an essential role for
sumoylation in cell cycle progression. The major targets of SUMO in S. cerevisiae are the
septins, which function in the regulation of cytokinesis. Sumoylation plays a role in
controlling dynamics of so-called septin ring formation at the yeast bud neck during the
cell cycle (Johnson and Blobel 1999). In addition to yeast, the importance of sumoylation
pathway has been demonstrated in Drosophila and C. elegans. Drosophila Ubc9 was
recently shown to mediate the dissociation of chromosomes at the end of meiotic prophase
I (Apionishev et al. 2001), and C. elegans Ubc9 was demonstrated to be essential for
embryogenesis (Jones et al. 2001).
The proteins involved in sumoylation pathway (SAE1, SAE2, Ubc9 and SUMO-1)
are predominantly located in the nucleus (Azuma et al. 2001, Rodriguez et al. 2001), and
most of the sumoylated proteins identified thus far are nuclear (Kamitani et al. 1997).
However, there are also very well characterized, efficiently sumoylated, substrates, such as
RanGAP1 and yeast septins, that are restricted to the cytoplasmic compartment (Matunis et
al. 1996, Mahajan et al. 1997, Johnson and Blobel 1999). The nuclear localization signal
(NLS) is required for SUMO-1 conjugation of some substrates in vivo, suggesting that in
these cases proteins must be targeted to the nucleus to undergo SUMO-1 modification
(Rodriguez et al. 2001). The finding that RanBP2, which is localized to the cytoplasmic
filaments of nuclear pore complexes (NPCs), has SUMO-1 E3 ligase activity suggest that
NLS-containing targets of SUMO-1 modification can be modified on their way to the
nucleus (Pichler et al. 2002).
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Several proteins are modified by SUMO-1 (Melchior 200, Yeh et al. 2000, Müller
et al. 2001). SUMO is attached to lysine residues of the target proteins that are embedded
in the consensus sumoylation sequence ΨKXE (Melchior 2000, Yeh et al. 2000, Müller et
al. 2001). Even though SUMO-1 and SUMO-1-conjugating machinery is essential for the
normal growth of yeast, the role of sumoylation in mammalian cells is not well established.
However, the modification has been shown to be involved in the regulation of subcellular
and subnuclear localization of proteins as well as protein-protein interactions, stabilization
of proteins by preventing ubiquitination, and regulation of the activities of transcription
factors (Melchior 2000, Yeh et al. 2000, Müller et al. 2001).
4.2.1. Regulation of protein targeting and protein–protein interactions
The Ran GTPase-activating protein RanGAP1 was the first protein identified as a target for
SUMO modification (Matunis et al. 1996, Mahajan et al. 1997). RanGAP1 is a key
regulator of Ran GTPase, which controls the nucleo-cytoplasmic transport through the
nuclear pore complex (NPC). The SUMO-1 modification of RanGAP1 is required for the
interaction with RanBP2 that is localized at the cytoplasmic filaments of the NPC
(Mahajan et al. 1997). SUMO-1 is not directly mediating the interaction, but modification
has been suggested to induce a structural change in RanGAP1 that allows its binding to
RanBP2 (Matunis et al. 1996, Mahajan et al. 1997, Saitoh et al. 1997). RanBP2 is also
sumoylated, but the role of sumoylation in the function of RanBP2 is not known (Saitoh et
al. 1998). During mitosis, the localization of RanGAP1 to mitotic spindles and
kinetochores is also dependent upon the SUMO-1 conjugation of RanGAP1 (Joseph et al.
2002).
The PML nuclear bodies are nuclear speckles of unknown function containing
several different proteins (Maul et al. 2000). The PML bodies seem to be preferential
accumulation sites for sumoylated proteins (Yeh et al. 2000, Müller et al. 2001). The
defining component of the PML bodies, the PML protein, is sumoylated at three distinct
lysine residues, and sumoylation of PML is known to regulate the assembly and/or stability
of the PML bodies (Sternsdorf et al. 1997, Kamitani et al. 1998a and 1998b, Müller et al.
1998, Duprez et al. 1999, Zhong et al. 2000). The SUMO-1-modified PML is able to
recruit other proteins to the PML bodies. A transcriptional repressor Daxx is relocalized
and stored in an inactive state in the PML bodies upon sumoylation of PML (Ishov et al.
1999, Li et al. 2000). Daxx represses the transcriptional activity of Pax3 transcription
factor, and sumoylation of PML induces the activity of Pax3 through sequestration of Daxx
into the PML bodies (Lehembre et al. 2001).
Another component of the PML bodies, Sp100, is also a subject to covalent
modification by SUMO-1, but sumoylation is not needed for the localization of Sp100 in
the PML bodies (Sternsdorf et al. 1999). Instead, Sp100 interacts with chromosomal non-
histone proteins of the HP1 and HMG1/2 families (Lehming et al. 1998, Seeler et al.
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1998), and sumoylated Sp100 has a higher affinity for the HP1 protein (Seeler et al. 2001).
Further evidence for the role of sumoylation in the regulation of subnuclear localization is
provided by studies demonstrating that the SUMO-1-modified HIPK2, a transcriptional
corepressor of homeodomain transcription factors, is targeted to detergent-insoluble
subnuclear complexes (Kim et al. 1999), and that the ETS-related transcriptional repressor
TEL is found in cell-cycle-specific nuclear dots in a sumoylation-dependent manner
(Chakrabarti et al. 2000).
4.2.2. Sumoylation of transcription factors
Various transcription factors are targets for SUMO modifications, but the role of
sumoylation in the regulation of the functions of these proteins is still unclear. AR is
sumoylated in an androgen-enhanced fashion (Poukka et al. 2000). Mutation of SUMO-1
attachment sites in the N-terminal domain (lysines 386 and 520) of AR enhances
transcriptional activity of the receptor on minimal promoters (Poukka et al. 2000). The
transcriptional activities of c-Jun and c-Myb are also negatively regulated by SUMO-1
modifications, in that disruption of major sumoylation target lysines in these proteins
enhances their activity (Müller et al. 2000, Bies et al. 2002). p53 is also sumoylated, and
overexpression of SUMO-1 has been suggested to enhance the transcriptional activity of
wild-type p53, but not the sumoylation deficient p53 (Gostissa et al. 1999, Rodriquez et al.
1999). However, opposite results have also been reported (Kwek et al. 2001). p53 is
recruited into PML bodies by a specific PML isoform or by coexpression of SUMO-1, but
the recruitment is not dependent on the SUMO-1 modification of p53 itself (Fogal et al.
2000).
SUMO-1 modifications also regulate activities of heat shock transcription factor 1
(HSF1) and HSF2 that mediate the induction of heat shock protein gene expression in cells
exposed to elevated temperature and other stress conditions (Goodson et al. 2001, Hong et
al. 2001). In contrast to HSF2, which is constitutively modified, HSF1 is only modified
after stress treatment (Goodson et al. 2001, Hong et al. 2001). Mutation of the principal
sumoylation site of HSF1 was demonstrated to result in a decrease in its stress-induced
transcriptional activity (Hong et al. 2001). Sumoylation was suggested to convert both
HSF1 and HSF2 to active, DNA-binding forms (Goodson et al. 2001, Hong et al. 2001).
Interestingly, histone deacetylase 1 (HDAC1) is also a target for SUMO-1 modification,
and sumoylation appears to affect the activity of the enzyme, since mutation of the SUMO-
1 attachment site reduces HDAC1-mediated transcriptional repression (David et al. 2002).
In addition to transcription, sumoylation is connected to other DNA-dependent
processes, such as DNA repair. For example, topoisomerase I and II (TOP1 and II) are
substrates for SUMO-1 attachment, and the SUMO pathway has been suggested to be
involved in the repair of TOP1-mediated DNA damage (Mao et al. 2000a and 2000b).
SUMO-1 modification of human thymine-DNA glycosylase (TDG), an enzyme that
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initiates base excision repair and removes the aberrant bases, dramatically reduces DNA
substrate binding affinity of TDG, which is associated with a significant increase in
enzymatic turnover (Hardeland et al. 2002). 
4.2.3. Regulation of protein stability
If SUMO and ubiquitin compete for the same lysine residues in the target protein,
sumoylation may lead to stabilization of the protein by blocking ubiquitination and
subsequent degradation, as exemplified by the inhibitor protein IκBα (Desterro et al.
1998). IκBα is a regulatory protein that binds the transcription factor NF-κB and keeps
NF-κB inactive in the cytoplasm. Upon stimulation, IκBα  becomes phosphorylated,
which acts as a signal for ubiquitination and degradation of IκBα (Israel 2000).
Degradation of IκBα  releases NF-κB to the nucleus, where it regulates target gene
transcription. IκBα is SUMO-1 modified at the same lysine residue used for
ubiquitination, and sumoylation thereby stabilizes IκBα leading to inhibition of NF-κB
activation (Desterro et al. 1998). A similar role of sumoylation has been suggested in the
regulation of Mdm2 (murine double minute clone 2), an E3 ubiquitin ligase for p53
(Buschmann et al. 2000). However, a note of caution has been raised, since all available
data do not support this model (Melchior and Hengst 2000). Thus, the role of sumoylation
in the regulation of E3 ubiquitin ligase activity of Mdm2 remains to be solved.
4.3. Future perspectives
Genetic studies in yeast have demonstrated the important role of sumoylation in cell
growth and division, but the biological significance of SUMO modifications in mammalian
cells is still elusive. To find out the physiological importance of sumoylation, gene
targeting in mice is needed to specifically inactivate the different sumo genes or the genes
encoding components of SUMO-conjugating machinery. In addition, selective inhibitors
that block either sumoylation or SUMO deconjugation would be useful tools in
characterization of the function of sumoylation. Analogous inhibitors of proteasome-
mediated degradation, such as MG132, have had a marked impact on the study of protein
turnover and understanding the role of protein ubiquitination. At the same time,
identification of novel sumoylation substrates, as well as characterization of the effects of
sumoylation on their activities has to be continued to understand better the role of SUMO
modifications in the regulation of cellular functions.
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AIMS OF THE STUDY
The PIAS protein family is a small group of highly conserved nuclear proteins that interact
with many different transcription factors. Because of the high degree of sequence
homology, it is likely that PIAS proteins also share similar functions. Since
ARIP3/PIASxα was originally characterized as an androgen receptor coregulator, and
since two PIAS proteins, ARIP3/PIASxα and PIAS1, are highly expressed in testis, PIAS
proteins were assumed to play a role in androgen receptor-dependent signaling. The
domain structure of PIAS proteins and the mechanism underlying their function were,
however, largely unsolved. The following specific aims were addressed in this study:
•  To study the functions of different PIAS proteins in steroid receptor-dependent
transcription and to compare the effects of PIAS proteins in steroid receptor- and
STAT-dependent signaling
• To characterize the domains important for the function of ARIP3
•  To elucidate the mechanisms underlying PIAS protein action by searching for
interaction partners
• To examine the role of PIAS proteins in SUMO-1 modification pathway
• To study sumoylation of the steroid receptor coactivator GRIP1 and to elucidate the
effects of this modification on the GRIP1 function
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METHODS
More detailed descriptions of the methods and materials used in this study are found in the
original publications (I-IV) as indicated in the table below.
Table 2. Methods used in this study.
Method original
publication
Plasmid construction and recombinant DNA technology I, II, III, IV
Cell culture I, II, III, IV
Transfections and reporter gene assay I, II, III, IV
Mammalian two-hybrid assay I, II
Immunoprecipitation II, III
Production of recombinant proteins in bacteria I, II, III
Protein–protein interactions in vitro (GST pull-down) I, II
SDS-PAGE and immunoblotting I, II, III, IV
Detection of SUMO-1 modifications in intact cells III
In vitro SUMO-1 modification III
Immunocytochemistry III, IV
Confocal microscopy III, IV
THE SEQUENCES OF PIAS PROTEINS USED IN THIS STUDY
The full-length rat ARIP3 cDNA (Gene bank accession number AF044058) was obtained
by screening a rat testis cDNA library with the ARIP3 fragment found in the yeast two-
hybrid screen as a probe (Moilanen et al. 1999). Mouse PIAS3 (AF034080) and mouse
PIAS1 (AF077950) were generous gifts from Dr. K. Shuai (Los Angeles, CA). N-
terminally truncated mouse Miz1 (AF039567) cDNA lacking the sequence encoding the
first 131 amino acids was a kind gift from Dr. R. Maxson (Los Angeles, CA).
ARIP3/PIASxα and Miz1/PIASxβ are splice variants encoded by the same gene, and their
first 550 amino acids are identical. Full-length Miz1 was constructed by ligating
nucleotides encoding amino acids 1-337 of ARIP3 to the C terminus of Miz1 encoding
amino acids 338-621 (I).
37
RESULTS AND DISCUSSION
1. PIAS PROTEINS FUNCTION AS STEROID RECEPTOR COREGULATORS (I, II)
ARIP3 (androgen receptor-interacting protein 3) was originally found in a yeast two-
hybrid screen using the AR DBD and part of the hinge region as bait (Moilanen et al.
1999). ARIP3 also interacts with full-length AR and modulates AR-dependent
transcription (Moilanen et al. 1999). Other PIAS proteins have been shown to interact with
and to regulate activities of very dissimilar transcription factors (Chung et al. 1997, Valdez
et al. 1997, Wu et al. 1997, Liu et al. 1998). However, the high degree of sequence
homology among PIAS proteins predicts similar functions. The abilities of four PIAS
proteins – ARIP3/PIASxα, Miz1/PIASxβ , PIAS1 and PIAS3 – to modulate steroid
receptor-dependent transcription were studied by using transient transfections and reporter
gene assays. The fifth PIAS family member, PIASy, was not investigated in this study.
Different cell lines and different reporter constructs were used. All studied PIAS proteins
were able to modulate AR, GR, ER and PR-mediated signaling, but their effects differed
depending on the receptor, the promoter, and the cell type. On the minimal ARE2TATA
promoter, PIAS proteins enhanced both AR and GR-dependent transcription, but the
degree of enhancement varied according to the PIAS protein used. In HeLa cells, Miz1 and
PIAS1 were more potent coactivators of AR than ARIP3 and PIAS3. In contrast, ARIP3
enhanced GR-dependent transactivation from the minimal promoter more efficiently than
other PIAS proteins. The effects of PIAS proteins on complex promoters were more
diverse. Miz1 and PIAS1 activated AR-dependent transcription from the natural probasin
promoter, whereas ARIP3 repressed AR activity under the same conditions. Likewise,
ARIP3 repressed GR-dependent transcription from the mouse mammary tumor virus
(MMTV) promoter despite the fact that ARIP3 is very strong coactivator of GR on the
minimal promoter.
The differences among the effects of PIAS protein on AR and GR-mediated
transactivation on the minimal promoter were diminished in HepG2 cells, and all PIAS
proteins activated the function of AR and GR to a similar degree. Moreover, ARIP3 was
not able to repress the activity of AR from the probasin promoter in HepG2 cells. These
interesting differences in the cell line-specific functions of PIAS proteins may derive from
the differences in the expression of endogenous PIAS proteins or factors regulating the
function of PIAS proteins in these cells lines. Interestingly, PIAS proteins are able to
interact directly with other family members (Tan et al. 2002, our unpublished results). Tan
et al. (2002) also demonstrated that the coregulatory effects of PIAS1 on AR are
modulated by coexpression of PIASxα, PIASxβ or PIASy, suggesting that the net effect of
PIAS proteins is dependent on the relative amounts of different family members. Miz1 and
PIAS1, but not ARIP3 and PIAS3, exhibit some intrinsic transcription-activating function
38
both in HeLa and HepG2 cells. This is in line with the ability of Miz1 and PIAS1 to
activate AR-mediated transcription from both minimal and complex promoters, but not
with the results obtained in HepG2 cells. Thus, the transactivation functions of Miz1 and
PIAS1 cannot be the only explanation for the differences in the actions of PIAS proteins.
In summary, PIAS proteins are efficient modulators of steroid receptor signaling,
and they function in a receptor-, promoter- and cell line-dependent fashion. The effects of
PIAS proteins were prominent even with low amounts of expression plasmids transfected,
and under similar conditions, the effects of PIAS proteins on STAT-mediated transcription
were modest. Thus, under ectopic expression conditions, the action of PIAS proteins is
clearly not restricted to inhibition of STAT signaling, but they also function as coregulators
for steroid receptors. The role of PIAS proteins in steroid receptor-dependent signaling has
subsequently been addressed by other laboratories. The interaction of PIAS1 and AR was
discovered in a yeast two-hybrid assay, when a HeLa cell cDNA library was screened
using an AR region containing the DBD and the LBD as bait (Tan et al. 2000). PIAS1 has
been demonstrated to modulate the activities of AR, GR and PR (Tan et al. 2000, Gross et
al. 2001). Similarly, PIASxα, PIASxβ, PIAS3 and PIASy interact with AR and function as
AR coregulators (Junicho et al. 2000, Gross et al. 2001, Tan et al. 2002). These results
further confirm the involvement of PIAS proteins in steroid receptor-dependent
transcription.
2. DOMAINS IMPORTANT FOR COREGULATOR FUNCTION OF PIAS PROTEINS (I, II, III)
To modulate the steroid receptor-dependent transcription, PIAS proteins have to interact
with the receptors, either directly or indirectly. Direct interactions of full-length ARIP3 and
Miz1 with AR, GR, PR and ER was demonstrated in vitro in GST pull-down assays. The
interactions in this system were independent of the presence of the ligand. All four PIAS
proteins were also able to interact with AR in a ligand-enhanced fashion in mammalian
two-hybrid assay. In the original yeast two-hybrid screen, the C-terminal region (amino
acids 443-547) of ARIP3 was found as an fragment interacting with the AR DBD. The C
terminus of ARIP3 also interacted with full-length AR in mammalian two-hybrid assay
(Moilanen et al. 1999). Likewise, the C terminus of PIAS1 has been shown to mediate the
interaction with STAT1 (Liao et al. 2000). However, in coimmunoprecipitation
experiments, the C-terminally truncated ARIP3 (ARIP3∆467-547) interacted with AR as
efficiently as wild-type ARIP3, indicating that this region is not alone responsible for
binding to AR. Instead, the potential zinc-binding domain of ARIP3 (amino acids 347-418)
was mandatory for the interaction with full-length AR. Other groups have demonstrated
that the N terminus of PIAS1 (amino acids 1-318) and PIASy (amino acids 1-406) are
capable of interacting with the AR DBD in vitro (Tan et al. 2000, Gross et al. 2001).
Similarly, the DBD of AR is not the only region reported to be involved in the binding to
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PIAS proteins, since Junicho et al. (2000) showed that an intact N terminus of AR is
required for the interaction with PIAS3. In coimmunoprecipitation assays, deletion of
either the LBD or the DBD of AR weakened the interaction with ARIP3, but N-terminal
deletions of AR did not have marked effects on the interaction (unpublished results). In
conclusion, more than one functional domains in PIAS proteins and steroid receptors
mediates the interactions between these proteins in vivo. All the interactions are not
necessarily direct, but may be bridged by other proteins present in the same complex.
Fig. 8. The ARIP3 mutants used in this study and the summary of the properties of the mutants. The SAP
motif, the RING finger-like structure and the SUMO-1-binding motif are shown. Amino acids that were
mutated to study the functions of LXXLL motifs (Leu 23 and 304) and the RING finger-like structure (Trp
383, Cys 385 and Cys 388) are depicted. Interactions of ARIP3 and ARIP3 mutatants with AR (in
coimmunoprecipitation experiments), SUMO-1 (in GST pull-down) and Ubc9 (in GST pull-down) are
indicated with + (interacts) and – (does not interact or weakened interaction) signs. The capability of
different ARIP3 forms to modulate AR-dependent transcription on ARE2TATA and probasin promoters are
also shown: +, enhancement; –, repression; 0, no effect.
To find out which regions of ARIP3 are important for its function as a steroid
receptor coregulator, different ARIP3 deletion mutants were studied in transient
transfections (Fig. 8). In line with the finding that amino acids 443-547 interacted with AR
in the yeast two-hybrid screen, deletion of amino acids 467-547 abolished the ability of
ARIP3 to modulate AR-dependent transcription. This region also contains a serine-rich
acidic domain (amino acids 457-483) which is involved in the binding to SUMO-1. Since
deletion of the amino acids 467-547 did not abolish the interaction of AR with ARIP3 in
coimmunoprecipitations, it is possible that the inability of ARIP3∆467-547 to modulate
AR activity was due to the loss of some other interaction, such as binding to SUMO-1.
PIAS proteins harbor a putative DNA-binding motif, the SAP module (Aravind and
Koonin, 2000), at their N termini (residues 11-45 in ARIP3). Interestingly, when the first
100 amino acids of ARIP3, or amino acids 13-28 of the SAP motif were deleted, the ability
of ARIP3 to repress the AR-dependent transcription from the probasin promoter was
abolished (unpublished). These ARIP3 mutants were still able to interact with AR in
coimmunoprecipitation experiments. The SAP domain is thus important for the coregulator
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function of ARIP3, maybe through the SAP motif-mediated DNA binding. Our initial in
vitro DNA-binding assays using GST-ARIP3 have failed to show high-affinity DNA-
binding, but the N-terminally fused GST may have impaired the function of the SAP
module (unpublished results). Tan et al. (2002) have recently demonstrated that PIAS1
binds double-stranded A-T rich DNA, and the SAP module is needed for this binding. In
addition, Sachdev et al. (2001) showed that PIASy binds to nuclear matrix attachment
region (MAR) DNA, and the association with MARs and the nuclear matrix is mediated
via the N terminus of PIASy. Mutation of the two LXXLL motifs had only a modest effect
on the coregulator function of ARIP3, suggesting that the interaction between ARIP3 and
AR or GR do not rely on these motifs.
Seven cysteine residues and a histidine residue in the highly conserved central
region of PIAS proteins may potentially form a zinc-binding C3HC4-type RING finger
motif. Zinc fingers typically form interfaces for interactions with DNA and for protein-
protein contacts. Interestingly, the deletion of the ARIP3 zinc-binding structure had a
dramatic effect on the ability of ARIP3 to modulate transcription from the minimal ARE-
driven promoter, in that the deletion converted ARIP3 to a strong negative regulator of the
AR function. Point mutations of the conserved cysteines 385 and 388 to serines caused
similar effects, suggesting that this region in PIAS proteins indeed forms a zinc-
coordinated structure. ARIP3∆347-418 devoid of the zinc-binding structure did not interact
with AR in coimmunoprecipitation assay. However, the ARIP3(C385,388S) mutant that
behaved in a fashion similar to ARIP3∆347-418 in transactivation assays, was able to
interact AR. Hence, the effects of the zinc-binding structure mutants of ARIP3 cannot be
merely explained by the loss of interaction with AR. Most probably other domains of
ARIP3 are also involved in the binding to AR, or alternatively, some other, currently
unknown proteins that exist in the AR-ARIP3 complexes mediate the interaction in vivo.
One interesting possibility is that the SAP domain of ARIP3 and DNA binding are
involved in ARIP3 function, and ARIP3 with the deleted zinc-binding domain is still able
to bind DNA and in this way repress the activity of AR. However, when both the SAP
domain and the zinc-binding region of ARIP3 were deleted, the mutant ARIP3 still
repressed AR-mediated transcription, arguing against the role of SAP domain in the
repressive effect of ARIP3∆347-418 (unpublished results). In conclusion, the C terminus,
the SAP motif and the zinc-binding structure of ARIP3 all play roles in the coregulator
activity of ARIP3, but further studies are required to clarify the specific functions of these
domains.
3. PIAS PROTEINS ARE MODIFIED BY SUMO-1 (III)
SUMO-1 was found to interact with ARIP3 in a yeast two-hybrid screen using the full-
length ARIP3 as bait (unpublished results). In GST pull-down assay, ARIP3 bound
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strongly to SUMO-1 and also to the SUMO-1 conjugating E2 enzyme Ubc9. Deletion of
the amino acids 467-487 of ARIP3 abolished the interaction with SUMO-1. This region
contains a Ser-rich and Glu/Asp-rich stretches preceded by hydrophobic residues, and a
similar motif in PM-Scl75 has been shown to be sufficient for the interaction with SUMO-
1 in yeast (Minty et al. 2000). In addition to the PIAS family members and PM-Scl75,
many other proteins, such as PML, SAE2, HIPK2, HIPK3 and SNURF contain a motif
corresponding to the sequence of the SUMO-1-binding motif (Minty et al. 2000). Thus,
interaction with SUMO-1 may play a more general role in the function of these proteins.
The zinc-binding region of ARIP3 (amino acids 347-418), on the other hand, is involved in
the binding of Ubc9. Because of the interaction with SUMO-1 and  the E2 enzyme of
sumoylation pathway, it was pertinent to test weather ARIP3 and other PIAS proteins are
subjected to covalent modification by SUMO-1. Coexpression of SUMO-1 with ARIP3,
Miz1 or PIAS1 in COS-1 cells resulted in the formation of higher molecular mass bands
that were identified to be SUMO-1-modified PIAS proteins. In contrast, the sumoylation of
PIAS3 was very weak. The migration of the higher molecular mass bands of ARIP3 on
SDS-PAGE suggests that up to three SUMO-1 moieties can be attached to ARIP3 and that
the form containing two SUMO-1 moieties is the major sumoylated product in COS-1
cells.
Even though PIAS proteins are efficiently sumoylated, their sequences do not
contain consensus SUMO-1 attachment sites. Deletion of the zinc-finger region (amino
acids 347-418) dramatically weakened the sumoylation, and when the amino acids 346-475
were deleted, modification was completely abolished. Mutation of the lysine pairs 324 and
326, 379 and 380, 390 and 391, and 430 and 431 to arginines failed to alter the pattern of
ARIP3 SUMO-1 modification. Thus, it is still unclear which lysine residues of PIAS
proteins are used for attachment of SUMO-1. Since deletion of the central zinc-binding
region may cause improper folding of the protein and thereby lead to the loss of SUMO-1
modification, a converse experiment was performed in COS-1 cells to study the
sumoylation of ARIP3 regions 341-418 and 341-490 fused to green fluorescent protein
(GFP). GFP-ARIP3(341-490) was sumoylated, whereas no sumoylation of GFP-
ARIP3(341-418) was detected. This confirms that the central region of ARIP3 between
amino acids 419 and 490 contains at least one SUMO-1 attachment site.  To study weather
PIAS proteins can also be modified under cell-free conditions, an in vitro SUMO-1
modification system using purified GST-fusions of SAE1, SAE2, Ubc9 and SUMO-1 was
established. PIAS proteins were translated in vitro and incubated with recombinant
SUMO-1, SAE1/SAE2 and Ubc9 in the presence of ATP. ARIP3, Miz1 and PIAS1 were
modified by at least three GST-SUMO-1 molecules, but sumoylation of PIAS3 was
undetectable under these conditions.
In analogy to the SUMO-1-binding motif of ARIP3, many cellular proteins contain
short ubiquitin-binding motifs: ubiquitin-associated domains (UBAs) and ubiquitin-
42
interacting motifs (UIMs) (Hofmann and Falquet 2001, Buchberger 2002). UIM motifs of
endocytic proteins Eps15 and Eps15R have recently been confirmed to be responsible for
ubiquitin binding, and interestingly, also for monoubiquitination of these proteins (Klapisz
et al. 2002, Polo et al. 2002). In contrast, deletion of the SUMO-1-binding motif (amino
acids 467-487) did not abolish ARIP3 sumoylation, indicating that this region is not
needed for SUMO-1 modification of ARIP3. UBA motif-containing proteins have also
been shown to inhibit multiubiquitination by binding to substrate-anchored ubiquitin
(Buchberger 2002). Likewise, UIM domain has been suggested to have similar role in
blocking polyubiquitination of UIM-containing proteins by formation of an intramolecular
interaction between the UIM and the substrate-bound ubiquitin (Polo et al. 2002). ARIP3
devoid of the SUMO-1-binding motif was sumoylated to a greater extent than the wild-
type protein, and this mutant also promoted sumoylation of COS-1 cell proteins more
efficiently that wild-type ARIP3, suggesting that the motif could indeed have some
regulatory role in the function of ARIP3.
4. PIAS PROTEINS INTERACT WITH SUMO-1-MODIFIED PROTEINS AND COLOCALIZE
WITH SUMO-1 IN NUCLEI (III)
When a FLAG-tagged ARIP3 coexpressed with SUMO-1 in COS-1 cells was
immunoprecipitated with the anti-FLAG antibody and subsequently immunoblotted with
SUMO-1 antibody, many additional high molecular mass SUMO-1 immunoreactive bands
were detected. Since they were not detected with anti-FLAG antibody, it was assumed that
they represented other SUMO-1-modified proteins coimmunoprecipitating with ARIP3.
This hypothesis was confirmed by repeating the immunoprecipitation experiment after
denaturating treatment to break protein–protein interactions. When immunoprecipitated
samples were immunoblotted with anti-SUMO-1 antibody, only the bands corresponding
to SUMO-1-modified ARIP3 were detected. PIASy was also demonstrated to
coimmunoprecipitate SUMO-2-modified proteins from cell lysates (Sachdev et al. 2001).
Sumoylation and thiol groups seem also to be somehow involved in the interaction of
ARIP3 with AR, since AR coimmunoprecipitates with ARIP3 only when N-
ethylmaleimide (NEM) is present in the buffers. NEM is a cysteine protease inhibitor that
blocks the action of SUMO-1 deconjugating enzymes (Li and Hochstrasser 1999, Suzuki et
al. 1999). However, both unmodified and SUMO-1-modified AR was
coimmunoprecipitated with ARIP3, indicating that AR sumoylation is not needed for the
interaction. The role of ARIP3 sumoylation in the interaction remains to be characterized.
As NEM modifies free thiol groups, its effects may also be mediated by modification of
proteins that are involved in the ARIP3-AR interaction.
Since ARIP3 binds to SUMO-1 in vitro, it was tempting to speculate that
recruitment of sumoylated proteins is mediated by the SUMO-1-binding motif of ARIP3
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(amino acids 467-487). However, deletion of this region of ARIP3 did not abolish the
interaction with other sumoylated proteins, but the recruitment was affected, in that the
pattern of the recruited proteins was shifted to a lower molecular mass range. Deletion of
amino acids 347-418 of ARIP3, on the other hand, eliminated the recruitment of other
SUMO-1 modified proteins totally, indicating that the zinc-binding region of ARIP3 is
required for this function. However, the zinc-binding region in isolation was not sufficient
for the recruitment of sumoylated proteins, since no sumoylated proteins were
immunoprecipitated with GFP-ARIP3(341-418), whereas GFP-ARIP3(341-490), including
both the zinc-binding region and the SUMO-1-binding motif, was capable of tethering
sumoylated proteins.
Nuclear distribution of ARIP3 and other PIAS proteins display speckled pattern
when transfected into COS-1 cells and visualized by confocal microscopy using a
monoclonal antibody against the FLAG epitope and a rhodamine-conjugated secondary
antibody. The PIAS-containing granules are distinct from PML nuclear bodies as detected
by double staining of cells with anti-FLAG and anti-PML antibodies (Ulla Karvonen,
personal communications). GFP-SUMO-1 expressed alone is typically diffusely distributed
in the nucleoplasm, but forms occasionally granular structures that differ in size from those
formed by PIAS proteins. Interestingly, coexpression of PIAS proteins with GFP-SUMO-1
resulted in perfect colocalization of the two proteins in the same granules. Deletion of the
SUMO-1-binding motif of ARIP3 partially disrupted the colocalization, leading to fewer,
but bigger, granules and to a considerable amount of diffuse nuclear SUMO-1. The zinc-
binding region of ARIP3 was crucial for the targeting of ARIP3 and SUMO-1 to the
nuclear granules, since coexpression of SUMO-1 with ARIP3∆347-418 resulted in a
diffuse nuclear distribution of both proteins.
These results demonstrated that PIAS proteins are not only subject to covalent
modification by SUMO-1, but they are also able to bind other sumoylated proteins in cells
and to colocalize with SUMO-1 in nuclei. Even though the free SUMO-1-binding motif of
ARIP3 is an obvious candidate to mediate these functions, the deletion of the zinc-binding
structure had a more dramatic effect on the ability of ARIP3 to bind other sumoylated
proteins than that of the SUMO-1-binding motif. The zinc-finger region-deficient ARIP3
was not targeted to the nuclear granules, suggesting that incorrect targeting of this mutant
could be one explanation for its inability to recruit SUMO-1-modified proteins.
ARIP3∆467-487 was targeted to the nuclear granules, but the colocalization with SUMO-1
was affected. Since ARIP3∆467-487 is still efficiently sumoylated, the remaining granules
containing colocalized ARIP3 and SUMO-1 probably represent SUMO-1 covalently
attached to ARIP3. In conclusion, the regions of ARIP3 that are important for the binding
of SUMO-1 and Ubc9 in vitro and for the coregulator function of ARIP3 in AR-dependent
transcription, also influence intranuclear targeting of ARIP3 and its association with
SUMO-1 and SUMO-1-modified proteins.
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5. PIAS PROTEINS MODULATE TRANSCRIPTION FACTORS BY FUNCTIONING AS SUMO-1
E3 LIGASES (III, IV)
The fact that ARIP3, Miz1 and PIAS1 interact with other sumoylated proteins and possess
a peculiar sumoylation feature, i.e., they lack consensus SUMO-1 acceptor sites, suggest
that these proteins participate in the sumoylation process itself. Many ubiquitin E3 ligases
are able to ubiquitinate themselves, and autoubiquitination has been suggested to play a
role in the regulation of their activities (Joazeiro and Weissman 2000). For example, the
activity of Mdm2 is controlled by autoubiquitination and subsequent degradation (Fang et
al. 2000, Honda and Yasuda, 2000). Interestingly, one group of ubiquitin E3 ligases
contains RING fingers that are required for their ligase activity (Lorick et al. 1999,
Joazeiro and Weissman 2000), and the zinc-binding structure of PIAS proteins resembles
the C3HC4 RING finger fold of ubiquitin ligases.
The involvement of PIAS proteins in sumoylation pathway was investigated by
coexpressing ARIP3 with SUMO-1 in COS-1 cells and immunoblotting COS-1 cell lysates
with the antibody against SUMO-1. ARIP3 increased markedly the overall sumoylation of
COS-1 proteins. The zinc-binding region of ARIP3 was mandatory for this function,
because ARIP3∆347-418 was not able to enhance protein sumoylation. SUMO-1
modification of AR occurs at two lysine residues located in the N-terminal region (Poukka
et al. 2000). Coexpression of ARIP3 or PIAS1 in HeLa cells stimulated the attachment of
both endogenous and ectopically expressed SUMO-1 to AR. In line with these results, the
AR mutant lacking the LBD showed an impaired interaction with ARIP3 and had also
weakened sumoylation compared to the wild-type AR in intact cells (unpublished results).
Purified GST-ARIP3 was also able to enhance SUMO-1 attachment to AR in vitro.
Additionally, sumoylation of the purified recombinant c-Jun was promoted by GST-
ARIP3. c-Jun has previously been demonstrated to be SUMO-1 modified at the lysine
residue 229 (Müller et al. 2000). Interesting differences in the substrate-specificity of PIAS
proteins were observed, when SUMO-1 modification of the nuclear receptor coactivator
protein GRIP1 was studied. GRIP1 was sumoylated when coexpressed with SUMO-1 in
COS-1 cells. Cotransfection of PIAS proteins resulted in enhanced SUMO-1 modification
of GRIP1 in a PIAS protein-selective fashion. ARIP3 had only a modest effect, but Miz1
and especially PIAS1 strongly promoted the attachment of SUMO-1 to GRIP1. Thus,
different PIAS proteins seem to act as E3 SUMO ligases with dissimilar substrate
preferences for target proteins.
Deletion of the zinc-binding structure of ARIP3 abolished its ability to enhance
sumoylation of both AR and c-Jun in vitro, whereas the SUMO-1-binding motif of ARIP3
was not required for this function. c-Cbl and a number of other RING-type ubiquitin
ligases contain a conserved tryptophan residue in the RING domain, and this residue is
critical for the E3 ligase activity of c-Cbl (Joazeiro et al. 1999). PIAS proteins also harbor
a conserved tryptophan in the middle of their RING finger-like structure (Fig. 2), and
45
mutation of this tryptophan to alanine abrogated the ability of ARIP3 to enhance
sumoylation of c-Jun and AR in vitro. Similarly, the RING-like domain of PIAS1 was
required for its E3 activity towards GRIP1, since the deletion of this region (amino acids
310-407) or mutation of tryptophan 372 to alanine converted PIAS1 inactive.
These results suggest that PIAS proteins function as E3-like ligases in the SUMO-1
modification pathway. They fulfill the criteria of E3 ligases, since they interact with
specific substrates and the E2 conjugating enzyme and promote sumoylation in a fashion
that is dependent on the RING finger-like domain. Contemporaneous studies from other
laboratories reported that Siz1 and a related protein Siz2 (Nfi1), yeast homologs of
mammalian PIAS proteins, promote sumoylation in yeast, and Siz1 was also shown to
enhance sumoylation of septins in vitro (Johnson and Gupta 2001, Takahashi et al. 2001b
and 2001c). In addition, PIAS1 and PIASy are able to enhance SUMO-1 modification of
p53 and LEF1, respectively (Kahyo et al. 2001, Sachdev et al. 2001), and Schmidt and
Müller (2002) demonstrated that PIAS1 and PIASxβ act as SUMO E3 ligases for c-Jun and
p53. In conclusion, the PIAS family members have been identified as the first
representatives of E3 SUMO ligases, underlying the importance of the PIAS protein family
in the SUMO-1 modification pathway (Fig. 9).
Fig. 9. PIAS proteins function as E3 SUMO ligases in the sumoylation pathway. S, SUMO-1. PIAS proteins
have been reported to enhance sumoylation of AR, GRIP1, c-Jun, p53, LEF1 and yeast septins. For more
details, see text.
As mentioned before, disruption of the zinc-binding structure of ARIP3 influenced
markedly the function of ARIP3 as a steroid receptor coregulator. Similarly, mutation of
Trp383, that abolishes the E3 SUMO ligase activity of ARIP3, converted ARIP3 from an
activator to a repressor of AR-dependent transcription on the minimal ARE2TATA
promoter. Deletion of the zinc-binding region of PIAS1, or mutation of the conserved Trp
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in this region, changed also PIAS1 function dramatically. It was somewhat surprising that
ARIP3 devoid of the SUMO ligase activity repressed AR function, since SUMO-1
modifications are shown to regulate negatively the activity of AR (Poukka et al. 2000). In
addition, the activity of the sumoylation-deficient AR mutant (K386R,K520R) on the
ARE2TATA promoter was repressed by ARIP3, in contrast to activation of wild-type AR
under the same conditions. However, the effects of PIAS proteins on the AR-dependent
transcription cannot be merely mediated through sumoylation of AR. PIAS proteins have
multiple interaction partners, and they are also able to influence the sumoylation of other
proteins involved in transcription, such as the coactivator GRIP1. Therefore, activation or
repression of transcription by PIAS proteins most likely reflects their combinatorial effects
on different factors regulating a given promoter.
Even though the SUMO-1-binding motif of ARIP3 was not required for either its
own sumoylation or the E3 ligase activity, the motif was critical for the coregulator
function of ARIP3 on AR-dependent transcription: deletion of this motif (amino acids 467-
487) abolished the ability of ARIP3 to modulate the activity of AR. Thus, the SUMO-1-
binding motif seems to have a role in the function of ARIP3 that is distinct from the
SUMO-1 ligase activity. Endocytic proteins with ubiquitin-interacting motifs play a role in
targeting of monoubiquitinated membrane proteins to endocytic pathway (Polo et al. 2002,
Raiborg et al. 2002, Shih et al. 2002). Ubiquitinated proteins and ubiquitin-binding motif-
containing proteins have been proposed to form an extensive network of interactions that
could influence many aspects of cellular physiology (Polo et al. 2002). Likewise, the
SUMO-1-binding motifs of cellular proteins may have a role in formation of interactions
with sumoylated proteins and in targeting of proteins to specific cellular locations. Neither
the sumoylation of AR nor the SUMO-1-binding motif of ARIP3 was required for the AR-
ARIP3 interaction in coimmunoprecipitation experiments. However, the SUMO-1-binding
motif may mediate the interaction of ARIP3 with other sumoylated proteins involved in the
AR-dependent transcription. Taken together, these results suggest that the modulatory
effects of PIAS proteins on steroid receptor-dependent transcription are in most cases
exerted through their SUMO-1-binding and SUMO-1 ligase activities.
6. SUMO-1 MODIFICATIONS REGULATE THE FUNCTION OF GRIP1 (III, IV)
GRIP1 (Hong et al. 1997, Leo and Chen 2000) was demonstrated to be subject to covalent
modifications by SUMO-1. GRIP1 was sumoylated at several lysine residues, since
coexpression of SUMO-1 with GRIP1 in COS-1 cells resulted in the formation of at least
four higher molecular mass bands, which were confirmed to be SUMO-1-modified GRIP1.
The possibility that the latter GRIP1 forms could result from the attachment of
polySUMO-1 chain was also considered, because Pichler et al. (2002) recently reported
that the nucleoporin RanBP2 is very efficiently modified by up to 25 molecules of SUMO-
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1, and polySUMO-1 chains are formed on RanBP2. Digestion of SUMO-1 modified
GRIP1 with the recombinant isopeptidase Ulp1 resulted only one digestion species
corresponding to one SUMO-1 molecule, suggesting that a single SUMO-1 monomer is
attached to more than one lysine residue in GRIP1 (unpublished results).
GRIP1 sequence contains four lysine residues (lysines 239, 731,788 and 1452) that
fulfill the consensus sumoylation sequence (Fig. 10). Mutation of lysine 1452 to arginine
did not affect the sumoylation of GRIP1, but lysine 239 and central lysines 731 and 788
were used as SUMO-1 attachment sites. Additional conjugation sites may exist, since
combined mutation of lysines 239, 731 and 788 did not abolish sumoylation totally. Lysine
66 is located in an incomplete consensus SUMO-1 attachment sequence, FKPD, and the
possibility that it is used as a residual SUMO-1 attachment site was considered. However,
combination of K66R mutation to other mutations did not reduce the sumoylation
(unpublished results). Mutation of the major sumoylation sites K239, K731 and K788 may
also lead to sumoylation of K1452 that is not otherwise subjected to modification.
Fig. 10. Structure of GRIP1. NID,  nuclear receptor-interaction domain; AD1 and AD2, activation domains 1
and 2; I, II and III, LXXLL motifs I, II and III. The roles of different NID regions in nuclear receptor binding
are shown. The regions interacting with different coregulators are indicated. Arrows depict the consensus
sumoylation sites (Lys 239, 731, 788 and 1452) (adapted from Ma et al. 1999).
The localization of GRIP1(K731,788R) in COS-1 cells did not differ from that of
wild-type GRIP1, as demonstrated by indirect immunocytochemistry and fluorescence
microscopy. However, the resolution of the confocal fluorescence microscopy may not be
good enough to detect subtle differences in localization. In addition, other methods such as
microscopy of living cells and photobleaching techniques are needed to visualize possible
kinetic differences in protein targeting. Lysines 731 and 788 are located in the nuclear
receptor interaction domain (NID) of GRIP1 containing the three LXXLL motifs used for
the interaction with NR LBDs (Ding et al. 1998, Leo and Chen 2000). Interestingly,
mutation of lysines 731 and 788 impaired the nuclear colocalization of GRIP1 with AR,
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indicating the importance of these sumoylation sites in targeting or recruitment of GRIP1
to AR-containing subnuclear sites.
SUMO-1 modifications are involved in subcellular and subnuclear targeting of
proteins (Melchior 2000, Yeh et al. 2000). Sumoylation of PML is required for its targeting
to nuclear PML bodies (Müller et al. 1998), and SUMO-1 modification of RanGAP1
directs the protein to cytoplasmic filaments of the nuclear pore complex (Mahajan et al.
1997). In addition, attachment of SUMO-1 to PML is needed for PML-mediated
recruitment of other proteins, indicating an important role of sumoylation in protein
complex formation (Ishov et al. 1999). SUMO-1 modification of GRIP1 could direct this
coactivator to transcriptionally active sites. It is currently unclear why colocalization of
GRIP1(K731,788R) with AR varied among the cells; the two proteins localized in separate
nuclear compartments in about half of the unsynchronized cells, whereas the other half
displayed colocalization pattern indistinguishable from that with the wild-type GRIP1.
Potential explanations include cell cycle related factors that influence nuclear architecture.
GRIP1 has been shown to localize to nuclear foci, a subset of which associates with the
PML bodies (Baumann et al. 2000), and it is plausible that sumoylation of GRIP1
influences the tethering of the coactivator to these bodies.  Interestingly, sumoylation of
PML and association of certain proteins with the PML bodies are indeed regulated with the
cell cycle (Everett et al. 1999, Grobelny et al. 2000, Wu et al. 2000).
In agreement with impaired colocalization of GRIP1(K731,788R) with AR,
mutation of lysines 731 and 788 blunted the transcriptional activity of GRIP1 on AR-
dependent transcription. Disruption of lysines 731 and 788 also attenuated the ability of
GRIP1 to activate the function of the AR LBD in isolation. However, the NID mutations
did not influence the capacity of GRIP1 to modulate the activity of AR AF1. Thus, lysines
731 and 788 seem to be important for the function of GRIP1 on the AR LBD. It is possible
that SUMO-1 modifications alter the binding of GRIP1 to AR. However, since LXXLL
motifs interact directly and specifically with NR LBDs, it is unlikely that SUMO-1
molecule attached to the lysine residue in the immediate vicinity of the LXXLL motifs
could strengthen the interaction. Thus, it is more likely that the effects on the transcription
are reflected from the targeting and colocalization of GRIP1 and AR.
It was somewhat unexpected that mutations of the SUMO-1 acceptor sites in
GRIP1 attenuated its ability to enhance the AR-dependent transcription, since elimination
of sumoylation sites from many DNA-binding transcription factors, such as AR, p53, c-Jun
and c-Myb, increases transcriptional activity (Gostissa et al. 1999, Rodriguez et al. 1999,
Müller et al. 2000, Poukka et al. 2000, Bies et al. 2002). However, it is possible that
SUMO-1 modifications of AR and GRIP1 occur at different stages of the AR transcription
complex formation to serve distinct roles in gene activation. A possible model, as
illustrated in Fig. 11, is that sumoylation of GRIP1 by the PIAS proteins recruits the
coactivator to AR-containing subnuclear sites. Subsequently, AR-bound GRIP1 recruits
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CBP/p300 and other coactivators to the promoter, and the target gene transcription is
activated. Sumoylation of AR may lead to displacement of the receptor from DNA after
the first cycle of transcription has commenced. In view of this model, sumoylation may
also regulate the function of other coactivators, such as CBP/p300, involved in the
regulation of transcription. Further experiments, such as chromatin immunoprecipitation
assays, are needed to confirm this model.
Fig. 11. A model representing the possible roles of SUMO-1 modifications in the AR-dependent
transcription. Unmodified GRIP1 localizes in subnuclear lumps that are distinct from AR-containing
granules. Sumoylation of GRIP1 by PIAS proteins recruits GRIP1 to AR-containing subnuclear sites.
Subsequently, AR-bound GRIP1 recruits CBP/p300 and other coactivators to the promoter and AR-
dependent transcription is stimulated. The specific effects of SUMO-1 modifications on AR function are still
unclear but sumoylation might lead for example to displacement of the receptor from DNA.
7. PIAS  PROTEINS COOPERATE WITH GRIP1 IN STEROID RECEPTOR-DEPENDENT
TRANSCRIPTION (II, IV)
The effects of PIAS proteins on steroid receptor-dependent transcription can be mediated
by the interactions with other coregulator(s) involved in the regulation of transcription.
Thus, it is important to identify interaction partners of PIAS proteins to better understand
their function. It was demonstrated that ARIP3, as well as Miz1, PIAS1 and PIAS3,
interact with the nuclear receptor coactivator GRIP1. In mammalian two-hybrid assay, the
C terminus of GRIP1 exhibited the strongest interaction with ARIP3. However, ARIP3
was also able to interact with the N terminus and the middle part of GRIP1, but to a lesser
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extent than with the C terminus. The C terminus of GRIP1 contains activation domain 2
(AD2) that has been demonstrated to bind the Zac1 protein and the arginine
methyltransferase CARM1 (Chen et al. 1999a, Huang and Stallcup 2000). The zinc-
binding structure of ARIP3 forms the interaction interface for GRIP1, since deletion of this
region, or mutation of two conserved cysteines of the zinc-binding structure, abolished the
interaction of ARIP3 with GIRP1, as demonstrated by mammalian two-hybrid assays and
immunoprecipitation experiments.
Coexpression of PIAS proteins and GRIP1 in HeLa cells resulted in a synergistic
enhancement of AR-dependent transcription. Miz1 and PIAS1 were more potent AR
coactivators than ARIP3 and PIAS3, and they also showed a more pronounced synergism
with GRIP1 on the AR-dependent transcription. These results correlate with the abilities of
PIAS proteins to promote sumoylation of GRIP1. Unlike other PIAS proteins, PIAS3 did
not act in a synergistic fashion with GRIP1. As discussed above, sumoylation of PIAS3
was also weaker than that of other PIAS proteins, but the possible connection between
these results requires further investigation. ARIP3∆347-418 and ARIP3(C385,388S)
mutants did not cooperate with GRIP1, attesting to the importance of the zinc-binding
region for ARIP3 function. ARIP3∆347-418 did not interact with either AR or GRIP1 in
coimmunoprecipitation experiments. However, it repressed the activity of AR, and when
coexpressed with GRIP1, it also blunted the GRIP1 coactivator function on AR-dependent
transcription. It is likely that in intact cells, ARIP3∆347-418 is still able to interact with
both AR and the central domain of GRIP1 through its other regions. These interactions
would, in turn, block the activity of AR and the ability of GRIP1 to activate the receptor
action.
The interactions of ARIP3 with AR and GRIP1 in vivo may be also stabilized by
some currently unknown proteins existing in the same complex. Good candidates are free
SUMO-1, other SUMO-1-containing proteins, or proteins of the SUMO-1 modification
pathway. The presence of the SUMO-1-binding motif in the ARIP3 sequence suggests that
this motif may play a role in the complex formation. The nature of ARIP3-AR-GRIP1
interactions and other proteins involved in the complex formation remain to be
characterized. The involvement of sumoylation in the interaction and cooperation of PIAS
proteins and GRIP1 is supported by the fact that the same region of ARIP3 needed for the
cooperation with GRIP1 is also required for ARIP3 to function as an E3-type SUMO-1
ligase. In addition, PIAS proteins – PIAS1 to the greatest extent – are able to promote
SUMO-1 modification of GRIP1. In keeping with these results, the synergistic effect of
PIAS proteins and GRIP1 was abolished when the main sumoylation sites of GRIP1 were
eliminated, indicating the crucial role that SUMO-1 modifications play in transcriptional
cooperation between GRIP1 and PIAS proteins.
In summary, this study has clarified the function of PIAS proteins by elucidating
their novel role as SUMO E3 ligases and SUMO-1-binding proteins. These activities were
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found out to be important for the ability of PIAS proteins to act as steroid receptor
coregulators. Furthermore, sumoylation of GRIP1 was described as a new mechanism to
regulate the function of this coactivator. Together these results suggest an emerging role of
sumoylation in the regulation of transcription. However, genetic studies using null mutants
are required to confirm the role that sumoylation and PIAS proteins play in vivo in steroid
receptor-dependent transcription. Specific inhibitors of sumoylation would also help to
elucidate the biological significance of SUMO-1 modifications in the transcriptional
regulation. Finally, the role of sumoylation in the assembly and/or disassembly of
transcriptionally active protein complexes on gene promoters remains to be assessed.
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CONCLUSIONS
The members of the conserved PIAS protein family modulate the signaling mediated by
AR and other steroid receptors. AR is covalently modified by SUMO-1, and in addition,
SUMO-1 modifications of other transcription factors and cellular proteins are emerging as
important factors in the regulation of protein-protein interactions and cellular targeting of
proteins. This study characterizes the function of PIAS proteins in steroid receptor-
dependent transcription and the role of PIAS proteins in the SUMO-1 modification
pathway. The results are summarized as follows:
 Ectopically expressed PIAS1, PIAS3, ARIP3/PIASxα and Miz1/PIASxβ modulate the
transcription mediated by AR, GR, ER and PR. These effects are dependent on the
receptor, the promoter and the cell line, and PIAS proteins can function as both
coactivators and corepressors. PIAS1 and Miz1, but not ARIP3 and PIAS3, contain an
intrinsic transcription activation function.
 PIAS proteins interact with both SUMO-1 and Ubc9. They colocalize with SUMO-1 in
the same nuclear granules and are able to recruit other sumoylated proteins in a non-
covalent fashion. PIAS proteins are themselves covalently modified by SUMO-1, and
importantly, they also act as E3 SUMO-1 ligases capable of enhancing sumoylation of
different proteins, such as AR, the steroid receptor coactivator GRIP1 and c-Jun. The
E3 SUMO-1 ligase activity is dependent on the conserved RING finger-like structure
of PIAS proteins.
 GRIP1 is sumoylated at multiple lysine residues. Mutation of the major sumoylation
sites of GRIP1 blunts its coactivator function in steroid receptor-mediated transcription
and impairs nuclear colocalization of GRIP1 with AR.
 PIAS proteins and GRIP1 interact with each other, and they are able to cooperate in
steroid receptor-dependent transcription. The cooperation of PIAS proteins and GRIP1
is dependent on the PIAS RING finger-like structure and the sumoylation sites of
GRIP1.
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